Glutathione S-transferases and head and neck cancer by Ophuis, M.B.O.
  
 
Glutathione S-transferases and head and neck cancer
Citation for published version (APA):
Ophuis, M. B. O. (2003). Glutathione S-transferases and head and neck cancer. Maastricht: Universiteit
Maastricht.
Document status and date:
Published: 01/01/2003
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
Glutathione S-transf erases
and head and neck cancer
Financial support Abbott. Alk Abellö, Almlrall Prodesfarma. Alphatron Medical & Microwave Systems.
ARTU Biologicals Europe. Entermed. Glaxo Smith Kline. Hoorcomfort Nedertand. Mediprof. Ooms
Allergie, Pfizer, Schering Plough. Schoonenberg Hoorcomfort. Streukens Hoorapparaten. Veenhuis
Medical. VieCuri Medisch Centrum voor Noord-Limburg
ISBN 90-9017247-5
€ Michael B Oude Ophuis. Venlo 2003
Vormgeving en druk door Datawyse / Universitaire Pers Maastricht
Omslagillustratie door Maria Oude Ophuis
Glutathione S-transferases
and head and neck cancer
Proefschrift
ter verkrijging van de graad van doctor
aan de Universiteit Maastricht
op gezag van de Rector Magnificus
Prof. dr. A.C. Nieuwenhuijzen Kruseman
volgens het besluit van het College van Decanen
in het openbaar te verdedigen
op vrijdag 26 September 2003 om 12:00 uur
door
Michael Bernardus Oude Ophuis
geboren te Rotterdam in 1967
Promotor
Prof. dr. J.J. Manni
Co-promotor
Dr. W.H.M. Peters (Universitair Medisch Centrum Nijmegen)
Beoordelingscommissie
Prof. dr. ir. P.A. van den Brandt (voorzitter)
Dr. B.J.M. Braakhuis (Vrije Universiteit Amsterdam)
Prof. dr. G.J. Hordijk (Universiteit Utrecht)
Prof. dr. P. Lambin
Prof. dr. F.C.S. Ramaekers
Voor Marianne, Martijn en Janneke
Aan mijn ouders
TABLE OF CONTENTS
List of Abbreviations 8
Introduction to the Chapters
Chapter 1 11
General introduction: Genetic Polymorphisms in glutathione
S-transferases and head and neck cancer susceptibility; a review.
Subm/tted for pubf/cation
Chapter 2 27
Glutathione S-transferase M l and T l and cytochrome P4501A1
polymorphisms in relation to the risk for benign and malignant head
and neck lesions.
Cancer 1998; 82: 936-943
Chapter 3 41
Demographic variation in the distribution of the glutathione
S-transferase T l null polymorphism in Dutch healthy controls;
implications for genotype research in head and neck cancer.
Subm/tted for pubf/cat/on
Chapter 4 51
Plasma glutathione S-transferase Pl-1 levels in patients with head
and neck squamous cell carcinoma.
Cancer 1998; 82:2434-2438
Chapter 5 6 1
Polymorphisms of the glutathione S-transferase PI gene and head
and neck cancer susceptibility.
Head and Necfc 2003; 25: 37-43
Chapter 6 73
The association between glutathione S-transferase P I genotype and
plasma level in patients with head and neck cancer.
Laryngoscope 2001; 112: 462-465
Chapter 7 83
Multiple genetic polymorphisms in detoxification enzymes and head
and neck cancer susceptibility.
Chapter 8 89
Meta- and pooled analyses of GSTM1, GSTT1. GSTP1. CYP1A1
polymorphisms and risk of head and neck cancers.
Subm/tted for pub//cat/on
Summary, Conclusions, Discussion and Future Perspectives 109
Samenvatting, Conclusies, Discussie en Toekomstige Mogelijkheden 115
Dankwoord 121
Curriculum Vitae 125
BHNL benign head and neck lesions
°C degrees Celcius
Cl Confidence Interval
CYP cytochrome P 450
DNA deoxyribonucleic acid
EDTA ethylene diamine tetra-acetic acid
ELISA enzyme linked inmmuno sorbent assay
EPHX epoxide hydrolase
GSH glutathion
GST glutathione S-transferase (enzyme)
GST g/urato/one S fransferase (gene)
H hours
HN all sites of head and neck malignancies
HNSCC head and neck squamous cell carcinoma
He isoleucine
LR likelyhood ratio
Min minutes
N number of patients or controls
n.s. not specified
OR Odds Ratio
PAH polycyclic aromatic hydrocarbon
PCR polymerase chain reaction
RFLP restriction fragment length polymorphism
SCC squamous cell carcinoma
SSCP single strand conformational polymorphism
V volts
Val valine
X"* chi square
8
INTRODUCTION TO THE CHAPTERS
Head and neck cancer is the sixth most common cancer in the world. The definition of
head and neck cancer in this thesis includes squamous cell carcinomas of the oral
cavity, pharynx, and larynx. Other head and neck tumor localisations and other
histopathological types have been excluded from this study. The risk of head and neck
squamous cell carcinoma (HNSCC) is strongly associated with smoking of tobacco and
consumption of alcohol, both of which may be responsible for a considerable load of
(pre)carcinogens. Metabolism and detoxification of such exogenous harmful com-
pounds often occurs by phase I and phase II enzymes such as cytochrome P450 (CYP),
microsomal epoxide hydrolase (EPHX) and glutathione S-transferase (GST).
Because genetic polymorphisms exist in the cytochrome P4501/U, glutathione
S-transferase M l , 71. P I and EPHX genes, that may lead to complete absence
(GSTM1 and GSTT1) or altered (CYP1A1, GSTP1 and EPHX) enzyme activity, individu-
als bearing such genetic polymorphisms and therefore lacking a (partially) normally
functional enzyme, may be at higher risk of developing HNSCC. Therefore, next to
smoking and drinking habits, it is believed that also genetic factors may contribute to
the risk for HNSCC. The aim of this study is to determine whether genetic
polymorphisms of the CYP, EPHX or GST detoxification enzyme systems influence the
individual susceptibility for HNSCC.
Chapter 1 gives an overview of studies on genetic polymorphisms in biotransformation
enzymes in relation to head and neck cancer. In chapter 2, genetic polymorphisms in
CYP1A1. GSTM1 and GS7T1 are evaluated in relation to HNSCC susceptibility. Several
years later, we discovered that demographic variation may influence this outcome. In
chapter 3 we again evaluated the GSTM1, GS7T1 and GSTP1 genotypes, but now in
control populations recruited from both the Nijmegen and Maastricht regions. Chapter
4 describes the quantification of blood plasma GSTP1-1 enzyme levels in patients with
HNSCC to find out whether these values are suitable as tumor markers to monitor pro-
gression of HNSCC. Polymorphisms of the GSTP1 gene in relation to HNSCC are inves-
tigated in chapter 5. A study on the association between plasma GSTP1-1 enzyme
levels and the GSTP1 genotype is presented in chapter 6. A study on the number of
polymorphisms in the genes studied in this thesis in relation to HNSCC susceptibility, is
presented in chapter 7. Chapter 8 is an international collaborative meta analysis on
polymorphisms of the GSTM1. GS7T1, GSfPl and CYP141 genes in relation to HNSCC
susceptibility. The summary recapitulates the contents of the individual chapters.
In this thesis the genotypes and the enzymes of glutathione S-transferases are dis-
cussed. For a better distinction between these two, the genotypes or gene poly-
morphisms are printed in italic (e.g. GSTP1), whereas the enzymes are in normal print
(e.g. GSTP1-1).
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CHAPTER
GENERAL INTRODUCTION:
GENETIC POLYMORPHISMS IN GLUTATHIONE
S-TRANSFERASES AND HEAD AND NECK CANCER
SUSCEPTIBILITY; A REVIEW
Michael B Oude Ophuis\ Wilbert HM Peters?, Johannes J Manni'
•Dept. of Otorhinolaryngology, Head and Neck Surgery, University Hospital Maastricht,
The Netherlands
^Dept of Gastroenterology, University Medical Center Nijmegen, The Netherlands
Submitted for pub//cat/on
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Summary
Background The etiology of head and neck squamous cell carcinoma (HNSCC) may
be clOMly related to toxification-detoxification processes of products that appear du-
ring smoking and/or alcohol consumption. The individual susceptibility to HNSCC may
be determined by alterations of the detoxification process due to genetic polymor-
phisms of glutathione S-transferases (GSTs).
Methods Through an extensive search in PubMed and reference backtracking a se-
lection was made of all English publications that evaluated one or more GST polymor-
phisms in relation to HNSCC.
Results A review is given on all literature to this date where one or more GST poly-
morphisms are evaluated in a HNSCC population. The site, size, race, and Odds Ratio
are evaluated in the case and control populations.
Conclusions The studies on GST polymorphisms and HNSCC susceptibility published
so far have reported contradicting results. Possible explanations in the variations of
study results are given. Carefully designed, population-based studies will be
necessary.
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Introduction
The global incidence of head and neck squamous cell carcinoma (HNSCC) is approxi-
mately 5%. In several regions, the incidence of HNSCC is higher, which may be related
to the consumption of specific substances, toxic or carcinogenic for head and neck tis-
sues. Several individuals at risk for HNSCC can be readily identified by their excessive
consumption of alcohol or tobacco, where it is also known that synchronous consump-
tion of both substances increases the toxicity of the other (1). The incidence of HNSCC
in the high-risk alcohol and tobacco consumer-group is significantly higher compared
to non-consumers. Within this high-risk group however, the majority of the individuals
ultimately do not develop HNSCC and therefore seem to be not susceptible to these
hazardous substances. The question then arises: what is the explanation for this phe-
nomenon; why does a person with a moderate or high intake of alcohol and tobacco
contract HNSCC, whereas another person with comparable intake of both substances
does not? It is hypothesized that this may be due to inter-individual differences in
genetic susceptibility towards alcohol or tobacco.
One of the first steps in the initiation of head and neck cancer may be the binding of
reactive metabolites of alcohol or tobacco smoke constituents to the DNA of mucosal
cells. This process is strongly influenced by phase I and phase II enzymes which are
involved in the toxification or detoxification of ingested compounds. For instance many
polycyclic aromatic hydrocarbons (PAHs). chemicals that are present in large amounts
in tobacco smoke (2), after ingestion may be first activated by phase I enzymes such
as cytochromes P450 (CYP) or epoxide hydrolases (EPHX) to become potential carcino-
gens, which subsequently need to be detoxified by phase II enzymes such as the
glutathione S-transferases (GSTs). An imbalance between the phase I and phase II
drug metabolizing or detoxification enzymes may contribute to the individual suscepti-
bility to HNSCC (see diagram 1).
Ph^a I a
/ • / ' /
Potential ~p
Carcinogen ^
ruyma • - ^ " / . . , - / \
Phas« II enzyma
Diagram 1 Schematic presentation of the detoxification of carcinogens by phase I and phase II
enzymes (a. and b. respectively). (PAH: polycyclic aromatic hydrocarbons)
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As a result of conjugation with glutathione, catalyzed by the glutathione S-transfer-
ases, the potential carcinogens are eliminated and DNA or other important
biomolecules are protected against damage or adduct formation (3-6). In humans, the
GST enzymes can be divided into four main classes: Alpha (GSTA), Mu (GSTM), Pi
(GSTP) and Theta (GSTT). Each class consists of one or more isoenzymes with different
but sometimes overlapping substrate specificities (5,6). At present genetic
polymorphisms have been demonstrated in GS7M1, GS7T1, GS7A1 and GS7P1(6-11).
Many polymorphisms in genes coding for risk modulating proteins or enzymes have
been identified recently which appear to be related to the risk for a number of diseases.
Therefore, it seems important to investigate whether the differences in susceptibility
towards alcohol and tobacco as described above, can be attributed to genetic variations
In systems that are involved in the detoxification of alcohol or tobacco-related carcino-
gens. Head and neck tissues, which are often exposed to alcohol or tobacco smoke, are
protected by enzyme systems such as the glutathione S-transferases.
Glutathione and glutathione S-transferase system
Glutathione (GSH) is an intracellular thiol that neutralizes precarcinogenic and highly
reactive electrophillic compounds, a process most commonly taking place by enzy-
matic conjugation catalyzed by glutathione S transferases (GSTs). GSH is produced
mainly in the liver (hepatocytes), and to a lesser extent in other cell types such as head
and neck mucosal cells, by coupling of the amino acids glycine, cysteine and glutamic
acid (12). When the GSH production is reduced or GSH is depleted, more electrophillic
compounds may freely circulate and may cause damage to DNA or other important
biomolecules. Since detoxification by GSH is strongly coupled to the GST enzymes,
also a reduction or deficiency of GST isoforms in a similar way may result in higher lev-
els of (DNA) damage.
Any factor that may disturb the metabolic balance of detoxification, can result in
increased levels of carcinogenic compounds and in an increased risk for developing
cancer. In this way GSH and GSTs may regulate the ability of each individual to metab-
olize environmental carcinogens.
Genetic polymorphisms, mostly resulting in significant reduction of corresponding
enzyme activities, have been described in GS7M1, GSTT1, GSIP1, and GS77U ('S-!!;.
For GSTM1 and GS7T1, nu// polymorphisms may be present, resulting in complete
absence of enzyme activity. The fact that GSTM1 and GS7T1 nu// genotypes in Cauca-
sians are common (20-50%), implicates that their co-occurrence is also relatively com-
mon (approximately 10%), which suggests that their possible contribution to the
susceptibility to HNSCC could be of considerable importance.
The polymorphism in GSTP1 may result in considerable loss of the corresponding
GSTP1-1 enzyme activity (13,14). The polymorphism in GSL41 probably is also wide-
spread and may have significant consequences for the corresponding enzyme activi-
ties but it has hardly been studied yet since it was described only recently (11).
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The studies performed so far have provided the following information: GSTVfl and
GS7T1 nu// genotype frequencies are highly variable in the HNSCC case populations
which have been studied (range 43 - 78 % for GSTM1 nu//. and 9 - 59 % for GSTT1 nu//;
see Table 1 and 2 respectively). However, similar variable frequencies are also seen in
the control populations studied by the same researchers. When patients are selected
according to HNSCC tumor site, also similar varying GST" nu// frequencies are reported.
HNSCC susceptibility of individuals with the GST nu// genotype however, appears to be
similar in most studies with non-nu//genotype individuals. However, it may be hypothe-
sized that susceptibility is higher when interaction of GSTs with other factors such as
tobacco smoking and/or alcohol consumption is considered. It appears however, that
the contribution of the GST nu// genotypes in the susceptibility of HNSCC is small or
even absent, especially when compared to the main risk factors described before
(tobacco, alcohol).
A more detailed review on the literature with respect to studies on genetic poly-
morphisms in GSTs in relation to HNSCC is provided below.
GST genotypes and head and neck cancer
GSTM1 genotype
The GSTM enzyme family exists in different isoforms, where 5 have been Isolated In
humans. Specifically the GSTM 1 enzyme may be of interest for HNSCC, since it detoxi-
fies metabolites of benzo [a] pyrene and other epoxides, which are tobacco related car-
cinogens (6).The corresponding gene GSTM1 displays three different genotypes, two
functional (GSTM1 d and GSTM1 8) and one nonfunctional genotype (GSTM1 nu//)
have been identified. In Caucasian populations approximately 50% lacks the func-
tional genotypes GSTM1 A or GSTM1 ß (see Table 1). The GSTM1 nu// genotype fre-
quencies however, do vary in and between countries and races, which makes It
difficult for instance to compare the results of studies on Caucasians with those of
other racial populations. Many studies reported a high frequency of GSTM1 nu// for
other sites of cancer than head and neck. Considering the studies on HNSCC, as
shown in Table 1, this seems not the case.
Kihara et al. (15) in Japanese smokers found that the GSTM1 nu// genotype was not
associated with laryngeal cancer eventhough there was a link to the smoking history.
In smokers with non-laryngeal HNSCC, however, GSTM1 nu// genotype was observed
more frequently (62.7%) as compared to controls (48.7%) (OR 1.8; Cl 1.0-3.0)(15). The
same authors suggest that GSTM1 nu// genotype also may be a potential risk factor for
HNSCC depending on smoking history.
Several research groups found no significant association between GSTM1 nu// geno-
type and any head and neck tumor localisation (16-22). Other researchers described
an increased risk for HNSCC related to the GST/vfl nu// genotype (23-25). Nair et al.
(26) in an Indian beetle quid or tobacco consuming population, found a significant
higher frequency of GSTM1 nu// genotype in patients with oral leukoplakia, a possible
precursor of oral squamous cell carcinoma. Cabelguenne et al. (27) reported no
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difference in frequency of GS7M1 in a HNSSC total group or several subgroups, except
for a subgroup of laryngeal cancer patients where an Odds Ratio of 2.6 (range 1.6-6.1)
was found for patients with the GSTM1 nu// genotype.
GSTT1 genotype
Similar to research on the GSTTvtl genotype, the GS7T1 gene is of interest because of
the capacity of the corresponding GSTT1-1 enzyme to detoxify alkyl halogenides, ethyl-
ene oxide, and other low molecular weight metabolic products. GSTT1 also displays a
genetic polymorphism resulting in a GSTT11 null phenotype being fully inactive. Since
the detoxification of many toxic low molecular weight compounds may be deficient in
individuals with the GS7T1 nu// genotype, such an individual may be potentially at risk.
The GS7T1 nu// genotype occurs in approximately 20% of a normal Caucasian popula-
tion. In other racial populations, this frequency may vary considerably as reported by
Nelson et al. (28). For instance Hung et al. (18) in a Taiwanese study described GS7T1
nu// genotype frequencies of 52.9% and 58.5% in controls and cases respectively (see
Table 2).
In contrast, there appears no racial difference in the data of Hung et al. (18) on GSTMl
nu// genotype rates compared to those of other investigators (see Table 1). However, in
accordance with most results by other groups (see Table 2), Hung et al. did not find
association of GS7T1 nu// genotype and HNSCC susceptibility. Furthermore, it is sur-
prising that Jahnke et al. and Matthias et al. (29-31), who used overlapping patient
and control samples, did reach different conclusions on the GS7T1 nu// genotype as a
factor of HNSCC susceptibility.
There appears to be an interaction with the degree of tobacco smoke exposure In sev-
eral studies. Olshan et al. (32) analysed tobacco users and non-users and revealed no
indication of increased risk among moderate users with the GS7T1 nu// genotype. How-
ever GS7T1 nu// genotype individuals having smoked more than 40 pack years showed
a higher OR compared to individuals with a functional gene. Also Hamel et al. (33)
found a significant increase in OR for HNSCC in GSTT1 nu// light smoking individuals
(OR 6.53; Cl 2.25-19.0).
GSTP1 genotype
The enzyme GSTP1-1, encoded by the GSTP1 gene, is also involved in the detoxifica-
tion of tobacco related carcinogens (6). GSFP1 displays two variant genotypes GSfPl
46 and GSTP1 66 next to the most common GSTP1 A4 genotype. In a normal control
population, the frequency of the GSTP1 44 genotype ranges from approximately
40-70%. The variant GSFP1 genotypes show a decreased specific activity and affinity
for substrates of the corresponding GSTP1-1 enzyme, since the polymorphism results
in an amino acid substitution near the substrate binding site area of the enzyme (8).
Since the GSTP186 genotype occurs only in approximately 10% of the population, the
two variant genotypes GSTP1 48 and GS7P1 68 have been combined in Table 3. As
seen for GS7T1, for GSIP1 also a strong correlation with race was found. Morita et al.
(34) in a Japanese population found significant lower frequencies of the variant GSTP1
48 and GSTP1 88 genotypes for controls and cases as compared to Caucasian study
groups. The genotype frequencies in another Japanese population with HNSCC
described by Katoh et al. (35) are comparable to the frequencies found by other
17
TaMe 2. GS7T1 nu» genotype frequencies in control and HNSCC patient populations
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researchers in Caucasian populations. This is however not so for their controls. All
other studies were performed on Caucasian populations and show comparable fre-
quency percentages.
Katoh et al. (35) observed the frequency of GSTP1 AB/BB genotypes to be significantly
higher in never smoking oral cancer patients than control individuals (OR 2.78; Cl
1.1-7.5). This suggests that non-smoking individuals with GSfPl AB or BB genotype
have a higher susceptibility for oral cancer.
Jourenkova et al. (36) reported no interaction of the GSTP1 gene and oral or pharyn-
geal cancers separately, however, when these two patient groups were combined, only
a borderline significant increase in risk of developing cancer of the oral cavity and
pharynx was found (OR 1.6; Cl 1.0-2.8). Matthias et al. (37) suggest that different sites
of HNSCC may be associated with different GST polymorphisms, since the GSTP1
AB/BB genotypes show lower frequencies in patients with laryngeal. but not with
oropharyngeal malignancies.
Discussion
The reason for the variable results with respect to the genetic polymorphisms In GSTs
and their association with HNSCC, as found in the many studies summarized in the
Tables 1-3, is not clear. Possibly the effect of one variant genotype on HNSCC suscepti-
bility is too weak. Perhaps the occurrence of more than one genetic polymorphism In
phase I and/or phase II enzymes, acting as a cascade, will have more effect and may
significantly influence individual susceptibility. Many conflicting reports on the cancer
susceptibility of GST genotypes have been published in the past decades. Most of
these studies have been conducted for other localisations than head and neck cancer.
Possible explanations in such variations in study results will be given.
Several reports describe patients with nu// genotypes of GSTM1 and/or GS7T1 who
had an increased oral cancer risk compared with individuals who had non-nu// geno-
types of both GS7M1 and GS7T1, suggesting that there are gene gene and gene envi-
ronment interactions in the development of oral cancer (18). The combined GS77W3
(AB or BB) and GSTM1 nu// genotype conferred a 4-fold risk of laryngeal cancer as
compared with the combined GS7M3 AA and GSTM1 positive genotypes (38). How-
ever, the effect of GSTM3 (AB or BB) genotype was similar among individuals with
GSTM1 pos/t/Ve or GSTM1 nu// genotypes (38).
Combined nu// genotypes of GSTM1 and GS7T1 prevailed in 60.2% of Indian cases
with oral leukoplakia whereas no individuals with this combination were detected in a
control group (26). This is a striking difference, which however may be due to racial dif-
ferences or due to the use of different methods for the isolation of DNA. since control
and patient material in this study was processed completely different (26).
Coutelle et al. (24) found that alcoholics (defined as individuals consuming more than
100g ethanol per day during at least 10 years) with the GSIM1 m/M genotype who were
also homozygous for a polymorphism in alcohol dehydrogenase (ADH), denoted as
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Table 3. GSTPl genotype (GSTPl AB and GSTPl BB) frequencies in control and HNSCC patient populations
GSTPl A& B6 Cases PopulationSite
HN
Larynx
Larynx
Oral
Pharynx
HN
Larynx
Oropharynx
HN
Larynx
Pharynx
HN
HN
Oral/ oropharynx
Larynx
HN
Oropharynx
HN
Oral
GSTPl AB/88
Controls
*- of total (n)
53.0 (264)
46.9(216)
50.0(172)
50.0(172)
50.0(172)
49.0 (25)
47.2(180)
47.2(180)
53.2(124)
31.1(164)
31.1(164)
31.1(164)
60.0(168)
56.1(285)
56.1 (285)
56.1 (285)
46.9 (216)
50.0(172)
23.8(22)
Countty Odds Rat»
(95% CD
No association of GSTPlAB/BB
genotype and HNSCC
Cabelguenneetal. (27)
Jahnke et al. (58)
Jourenkova et al. (38)
Jourenkova et al. (36)
Keiders et al. (48)
Matthias et al. (37)
Matthias et al. (37)
McWilliams et al. (52)
Morita et al. (34)
Olshan et al. (32)
Oude Ophuis et al. (47)
Association of GSTPl AB/Bfl
genotype and HNSCC
Jahnke et al 158)
Jourenkova et al. (36)
Katoh et al. (35)
n- total number of patients or controls in group, n.s.- not specified, HN - all sites of head and neck malignancies. Cl
* of total in i
45.0(162)
51.5 (n.s.)
51.9(129)
58.2 (67)
58 0(50)
58.6(51)
51.512601
62 5(120)
58.9(146)
18 9 (69)
26 6 (45)
24 9(145)
63 0(109)
53 5(114)
49 0(1001
50 6 (235)
62 5 (ni.)
58 7(121)
37 3(83)
: he
n.s.
rmraiian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Japanese
Japanese
Japanese
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Japanese
 • confidence interval
France
Germany
France
France
France
The Netherlands
Germany
Germany
USA
Japan
Japan
Japan
USA
The Netherlands
The Netherlands
The Netherlands
Germany
France
Japan
2.8(0 9-8-1)
n.s.
1.1 (0.7-2.0)
1.5 (0.8-3.0)
1.7 (0.8-3.4)
0.5(0 2 10)
0.8(0 4 14)
1.3(0.8-2.0)
as.
n.s-
n.s.
1.2(0.8-1.9)
0 8(0416)
0.9(0.5-1.8)
1.0 (0.6-1.7)
n.s.
1.6(1.0-2.8)
1.9(1.0-3.6)
which is associated with a rapid generation of acetaldehyde. had at
least an 80% greater risk of developing laryngeal cancer than alcoholics who were
GSTM1 positive and who were not bearing the ADH^/ADH^ genotype.
Individuals with concurrent lack of both functional GSfMl and GSTT1 genes had a ten-
dency for a higher risk of laryngeal cancer as compared with those individuals having
at least one of the above mentioned functional genes (OR 2.0; Cl 0.8-5.2), and had an
almost a 3-fold higher risk (OR 2.7; Cl 1.0-7.4) when compared with individuals having
both functional genes (23). These data suggest that a combination of genetic
polymorphisms in detoxification enzymes, either phase I or phase II, could modulate
the risk for malignant degeneration.
There are also studies that have shown an association between smoking and nu//
genotype. Kihara et al. (15) found more individuals bearing the GSTM1 nu// genotype
in the smoking patient group than in the healthy control group (56.7% vs 48.5%).
whereas there was an equal distribution in gender. The same authors also described a
smoking (n=128) and non-smoking (n«30) HNSCC group, and found a higher fre-
quency of GST/vfl nt/// genotype in the former group. HNSCC patients usually are smok-
ers, and the higher frequency of GSIMl nu// genotype in this group may suggest a role
for GS7M1 in the detoxification of tobacco smoke constituents.
However, associations found are not straightforward, since Park et al. (17) observed
no association between the prevalence of GSTM1 nu// genotype and the levels of
smoking or alcohol consumption in the HNSCC cases, whereas Jourenkova et al. (23)
found that the GSTM1 nu// genotype was associated with an increased risk of larynx
cancer among individuals who smoked 20 cigarettes/day or less but not among more
heavier smokers. No interaction was found between GS7"M1 nu// genotype and dura-
tion of tobacco consumption. For the GS771 nu// genotype. Jourenkova et al. (23)
found the opposite result; no interaction between levels of tobacco consumption, but
limited effect by long term smokers. Katoh et al. (39) found no effect of GSIM1 and
GS7T1 ni/// genotypes on oral cancer in combination with smoking or drinking. The GST
genotype of an individual may determine his smoking behavior in a similar way as the
ADH genotype may influence alcohol consumption.
Differences in the way the GST system is assessed may explain part of the conflicting
reports on the susceptibility of GSTs. There are studies that evaluated phenotypic
expression of GSTs in relation to HNSCC (40-46), whereas others evaluated the
genetic polymorphism (15,20,23,31,36-38,47) or a combination of both (48).
The collection of cell material for genotyping is different in the various studies. DNA iso-
lation from peripheral lymphocytes/leukocytes (18.20,23.25.36,38.47-49) is the
method of choice for genotyping. DNA isolation from tumor tissue, and especially par-
affin embedded tissue (26). may not be as reliable due to possible mutations that may
have occurred during carcinogenesis. Also, the use of DNA extracted from tissues pro-
cessed in a different way, such as exfoliated (buccal mucosa) cells in the control group
and paraffin embedded tissue in the patient group, as performed by Nair et al. (26)
may introduce artefacts.
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The moment of patient sampling (before, during, or after treatment) may influence the
phenotypic, and to a much lesser extent the genotypic expression of the GST system,
either locally or systemically. since it is well known that such therapies may generate
new mutations. Results obtained from previously untreated patients therefore may be
different compared to those having received earlier radio- or chemo-therapy. No men-
tion of this has been made in any study published so far.
Note the extreme small groups of cases as well as controls by Hanna et al. (50), which
makes it difficult to correctly interpret the results.
Combination studies with other than GST genes make interpretation of results more
difficult and not transparant, for instance evaluation of GSTs with other genes such as
p53 and p l 6 (22). However, it should be realized that GST enzymes most likely do not
act as a stand alone system for carcinogenesis but probably act together with other
enzymes or proteins.
In conclusion, we found that most studies conducted on the association between
genetic polymorphisms in GSTs and the risk for HNSCC are difficult to interpret. Sev-
eral factors, such as small sizes of control and patient populations studied, variations
In the methods used, interracial-, demographic- or other differences in the patient and
control populations studied may contribute to the variable results obtained so far. The
finding that high consumption of alcohol and tobacco is a predominant factor for
HNSCC has invariably been shown in most studies, whereas interaction with genotype
could be demonstrated only now and then. New studies witn mucn larger patient ana
control populations, or a meta analysis where all these contributing factors are criti-
cally evaluated and discussed would be highly desirable.
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Abstract
Background Susceptibility to head and neck cancer in a particular individual may de-
pend In part on the metabolic balance between phase I enzymes such as cytochromes
P450 (CYPs) and phase II enzymes such as glutathione S-transf erases (GSTs). Genetic
variability in CYP and GST isoenzymes may contribute to individual differences in sus-
ceptibility to chemical carcinogenesis. GSTM1 and GSTT1 nu// genotypes as well as po-
lymorphic variants in the CVP1A1 gene were described which may determine in part
the risk for head and neck cancer.
Methods Polymorphisms of GSTM1, GS7T1, and CYP1A1 in whole blood were detec-
ted by polymerase chain reaction method (PCR) in: 185 patients with head and neck
squamous cell carcinoma (HNSCC), 78 patients with benign head and neck lesions
(BHNL) and 207 blood donors.
Results GSTM1 nu// genotype was demonstrated to be equally frequent in patients
with HNSCC (50.8%), patients with BHNL (47.4%) and blood donors (51.7%). GS7T1
nu// genotype occurred significantly more often in patients with BHNL (33.3%) as com-
pared to blood donors (20.3%), demonstrating that lack of GS7T1 may be a risk factor
for BHNL. Presence of the rare valine in the CYP1A1/Nco/ site was found in 33 (17.8%)
patients with HNSCC, in 20 (25.6%) patients with BHNL and in 34 (16.4%) blood do-
nors, t-or the presence of tfie i<ne cyloslite nucfeotide in the CV7»X4 '^A*sp/ sito thoso
frequencies were 17.8, 15.4 and 15.9%, respectively.
Conclusions The occurrence of polymorphic variants in the GST/vfl, GS7T1, and
CYP1A1 genes did not differ between the groups investigated, therefore indicating no
significant contribution to the development of head and neck cancer.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) appears to be related to smoking
and alcohol consumption (1-5). Polycyclic aromatic hydrocarbons (PAHs), present in
tobacco smoke or metabolites of alcohol, are precursors of chemicals that increase
the risk of cancer (6). One of the first steps in head and neck cancer may be the binding
of exogenic electrophillic compounds to the DNA of mucosal cells (7-9). Most PAHs first
require activation by phase I enzymes, such as cytochrome P4501A1 (CYP1A1). to be-
come an ultimate carcinogen. These activated forms may be subjected to detoxifica-
tion by phase II enzymes, especially glutathione S-transferases (GSTs). Thus,
genetically determined susceptibility to head and neck cancer may depend on the
metabolic balance between these enzymes.
Glutathione S-transferases are a family of dimeric enzymes, involved in the bio-
transformation of a large variety of compounds. GSTs catalyse the nucleophillic conju-
gation of glutathione to many different biologically active and potential carcinogenic
compounds (10-13), which may be further metabolized to mercapturic acids. As a re-
sult the possible toxins or carcinogens are eliminated. In humans, the GST family can
be divided into class Alpha (A), Mu (M), Pi (P) and Theta (T) enzymes, each class con-
sisting of several isoenzymes with a (partly) overlapping substrate specificity (12,13).
Genetic polymorphisms have been demonstrated for the genes coding for the GSTM1
and CCTTi «wj-mM
The GSTM1 enzyme is involved in the detoxification of tobacco related carcinogens,
like epoxides and hydroxylated metabolites of benzo|a)pyrene (13). Two functional al-
leles (GSTM1M and GSTM1*B) and a non-functional nt///-allele (GS7Ml*0) have
been identified in the GSTM1 gene. Approximately 45% of the human Caucasian popu
lation lacks a functional allele (14-17). In olher ethnic groups this proportion may be
much higher (14). Carcinogenesis could be related to the absence of the functional
GS7M1 alleles resulting in an incapacity of detoxifying tobacco related carcinogens.
Several studies have shown that the GSf/vfl polymorphism is associated with an in-
creased risk of lung, bladder, gastric, colorectal, skin and larynx cancer (14,18-25).
Other studies, however, revealed that the impact of the GSTM1 trait may be low or
even undetectable in different cancer populations (26-32).
The GSTT1 gene also has a functional and a non-functional allele. Approximately 20%
of the human Caucasian population lacks the functional allele (33), whereas in other
ethnic groups this percentage may be different (23,34). Since the GSTT1 enzyme is in-
volved in the biotransformation of several low molecular weight toxins such as
methyl-halogenids or ethylene oxide (13), part of the population lacking this enzyme
might be more susceptible to smoking or alcohol related cancers. Lack of the GSTT1
enzyme has been associated with bladder cancer (24), whereas other studies did not
find an association with lung and skin cancer (32,35).
Many chemical compounds are metabolically activated to forms that have deleterious
effects on organisms (36), and this metabolic activation is an obligatory initiation step
in human carcinogenesis. Cytochrome P450 plays a major role in the formation of
chemical carcinogens (37,38). Many isoenzymes of CYP have been found in humans.
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Genetic variability in these isoenzymes may be responsible for the individual diffe-
rences in susceptibility towards cancer (37.39). The CYP1A1 enzyme is involved in the
activation of benzo[a]pyrene and other aromatic hydrocarbons in tobacco smoke
(36-42). Two genetic polymorphisms have been demonstrated in the CVP1>U gene,
which both may result in an increased enzyme activity (43-45): (i) an isoleucine/valine
substitution in exon 7, the heme binding region (C/Pl^l/Nco/) (46.47), and (ii) a thy-
mine/cytosine point mutation in the 3' flanking non-coding region (CVPl/Jl/Msp/).
Both genetic polymorphisms seem to be involved in an increased susceptibility to
carcinogenesis of the lung (44,46-48). It has been suggested that homozygotes of the
variant allele of each mutation are correlated with an enhanced susceptibility to smok-
Ingrelated lung cancer in a Japanese population (31,44,46.47). No such relationship
has been observed in black and non-black populations of Rio de Janeiro (49) or in Cau-
casian populations (50-52), where the occurrence of the susceptible alleles is very
rare.
In the present study we investigated genetic polymorphisms in GSTM1, GS7T1 and
CVP1/A1 In patients with malignant and benign head and neck lesions (HNSCC and
BHNL respectively), in comparison with a group of healthy blood donors.
Materials and Methods
Patients and controls
A total of 185 patients with head and neck squamous cell carcinoma (HNSCC) were re-
cruited preoperatively or postoperatively during their scheduled outpatient visit at the
University Hospital Maastricht (The Netherlands) between 1994 and 1996 (mean age
59.6 ± 11.8 years; range 23 - 86). This group consists of 73 patients with larynx carci-
noma (mean age 61.6 ± 10.6 years; range 36 - 86), 76 patients with oral and
Table 1. Classification of patients with HNSCC
Site - subsite of tumor
Oral cavity
Oropharynx
Larynx
Other
floor of mouth
tongue
retromolar trigonum
alveolar process
mucosa cheek
tonsil
soft palate
overlapping areas
base of tongue
lateral wall
vallecular region
posterior wall
glottis
supraglottis
hypopharynx
neck metastases of unknown primary
nasopharynx
sinus
parotid gland
skin
Number of patients
17
11
7
4
2
12
6
5
5
3
2
2
49
24
16
11
3
2
2
2
Total 185
30
oropharynx carcinoma (mean age 57.8 ± 12.0 years: range 23 - 82) and a remaining
group of 36 patients (mean age 60.4 ± 12.6 years: range 28 - 86), consisting of carci-
nomas of the hypopharynx (n=16), nasopharynx (n-3), sinus (n»2), parotid gland
(n=2), skin (n=2) and neck metastases of unknown primary origin (n-11). Table 1
shows the classification of the patients according to tumor risk. Table 3 shows a fur-
ther specification.
Our second population consists of 78 patients with benign head and neck lesions
(BHNL) such as polyps, cysts, and vocal cord nodules (mean age 49.2 ± 15.9 years:
range 16 - 86). A further specification of these patients is presented in Table 2 and 3.
A group of 207 healthy blood donors (76 men; 131 women) recruited at the University
Medical Center Nijmegen, (The Netherlands) served as a control group (mean age
34.3 ± 11.5 years; range 19 - 64).
At the time when informed consent was obtained, medical and other anamnestic data
were obtained by interview. The investigations were approved by the Medical Ethical
Review Committee.
Table 2. Classification of patients with BHNL
Site type of lesion
Vocal cord nodules / cysts
Parotid gland pleiomorphic adenoma
Nose - polyps
Neck • cysts (medial / lateral)
Submandibular gland sialolrthiasis
Oral cavity leucoplakia
Oral cavity fibromas
Nose cyst
Tonsil - retention cyst
Number of patients
22
16
13
9(7/2)
8
4
3
2
Total 78
Table 3. Age and gender of the patients with HNSCC (total group as well as subclasses). BHNL. and controls
HNSCC BHNL Control!
N
Age(yrs)
Mean • S.D
Range
Gender(%)
Male
Total group
185
59.6 ± 11.8
23-86
79.5
Larynx carcinoma
73
61.6 1 10.6
3&S6
88.2
Oropharynx carcinoma
76
57.8 ± 12.0
2382
70.7
78
49.2 1 15 9
16-86
46 8
207
34.31 11.5
1964
36.7
Female 20.5 11.8 29.3 53.2 63.3
Blood sampl ing and ext ract ion of DNA
Blood was collected by venapuncture in sterile siliconized EDTA K3 (15%) 4 ml
Vacutainer tubes (Becton Dickinson). Immediately after collection whole blood was
stored at -20'C until use. Genomic DNA was isolated from whole blood using the Wiz-
ard™ genomic DNA purification kit, according to the instructions of the manufacturer
(Promega. Madison Wisconsin. USA).
31
Genotyping
Genetic polymorphisms were detected by PCR and all primers were selected based on
studies by others. The primers were synthesized by Pharmacia Biotech (Roosendaal,
the Netherlands). All chemicals needed for PCR were purchased from Promega (USA).
For GS7M1 (primer set G2 and G3, ref. 27) and GS7T1 (primer set T l and T2. ref. 53)
one primer was situated in the deleted area. Genetic polymorphism in exon 7 of the
CYP141 gene was determined by PCR (primer set CVPJMl/l and CVPL41/2, ref. 48)
and restriction enzyme digestion according to Shields et al. (48). Here a primer was de-
signed so that the presence of the rare G allele (valine) results in the loss of a Ncol re-
striction enzyme site. Genetic polymorphism in the 3' flanking region in the CVP1A1
gene was detected by PCR and restriction enzyme digestion, using the primers C44
and C47 (44). Here, one of the primers was designed so that the presence of the rare C
nucleotide results in the appearance of a Mspl restriction enzyme site.
Fifty to hundred ng of DNA were amplified in a total volume of 25 pi containing 10 mM
Tris/HCI pH 9.0. 50 mM KCI, 0.1% Triton X-100, 2 mM MgCI? (1.5 mM for CVP1A1/1
and CVP1A1/2). 200 uM of deoxynucleotide triphosphate, 1 pM of each primer, and
0.2 units of Taq polymerase. overlaid with one drop of mineral oil. PCR was carried out
In a programmable Thermojet thermocycler (Eurogentec. Seraing. Belgium). After 5
mln of pretreatment at 95 *C. 35 cycles of 30 sec denaturation at 95 °C, 30 sec an-
nealing at 59*C (GSr/vfl and GS7T1) or 55°C (CVP1A1) and 90 sec extension at
72*C.
For evaluating GSr/vfl and GS7T1 polymorphisms, reaction mixture products were
analysed by gel electrophoresis (2% agarose; 60 V; 1 h) for the presence of a 650-base
pair product, which was indicative of the GS7M1 gene or a 480-base pair product, in-
dicative of the GS7T1 gene. The lack of an amplification product is consistent with the
nu// genotype. Detection of CVPI/U PCR products served as a positive control.
Amplification products of the CVPL41 gene were subjected to restriction fragment
length digestion using Mspl or Ncol (Promega; 10 units; 37 °C, 1.5 h). Analysis of the
Ncol site by gel electrophoresis (2% agarose; 60 V; 2.5 h) revealed a 163- and 32-base
pair fragments for wild type alleles (isoleucine) or a single 195 base pair fragment
when the mutation (valine) was present. Analysis of the Mspl site by gel electrophore-
sis (2% agarose; 60 V; 1.5 h) revealed a 340-base pair fragment for mutant alleles (cy-
tosine) or 200- and 140-base pair fragments for wild type alleles (thymine).
Statistical analyses
Statistical significance of differences for individual and combined polymorphisms be-
tween different groups was tested with a X* analysis with Yates correction in 2x2 or
2x4 contingency tables, respectively.
Results
The distribution of the GS7M1 and GS7T1 genes in patients with HNSCC or BHNL and
blood donors is summarized in Table 4. Presence of the GSTM1 gene in patients with
HNSCC (49.2%) did not differ significantly from the distribution in a population with
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either benign head and neck lesions (52.6%. p-0.71) or healthy blood donors (48.3%,
p=0.95). In subgroups based on tumor localisation (larynx and oral-oropharynx) these
expression frequencies were maintained (46.6% and 50.0%. respectively) and no sig-
nificant differences were obtained. The GSTMl polymorphism also did not show any
significant difference between benign head and neck lesions and blood donors
(p=0.61).
The BHNL group showed a significantly lower expression of the GS7T1 gene (66.7%) as
compared to the blood donor group (79.7%: X^ -4.6, p-0.03) and the HNSCC group
(80.5%: X^ =5.1, p=0.02). Compared to the blood donor population, the HNSCC group
showed no significant difference in GS7T1 expression (79.7% and 80.5%. respectively;
p=0.94). In the HNSCC subgroups no differences in GS7T1 gene distribution were
noted.
Presence of both GSTMl and GS7T1 genes occurred less frequently in patients with
BHNL as compared to patients with HNSCC (X^ =10.2, p-0.01), whereas no significant
difference was found between healthy volunteers and patients with BHNL or HNSCC.
Table 4. GSTM1 and GS7T1 expression in patients with HNSCC. BHNL and in control«
GSrMl*
GSFM1
GST71*
Gsm
Gsriwi'Gsm*
GsrMi'Gsm
GSTMl GS7T1*
GsrMi Gsnr
HNSCC (%)
91(49 2)
94 (50 8)
149 (80.5)
36(19.5)
79(42.7)
12 (6.5)
70(37.8)
24(13.0)
BHNL (%)
41(52.6)
37(47.4)
52(66.7)
26(33.3)
26 (33.3)
15(19.2)
26(33.3)
11(14.1)
Controls (%)
100 (48.3)
107(51.7)
165(79.7)
42 (20.3)
81(39.1)
10(9.2)
84 (40 8)
23(11.1)
*. gene present; .gene absent
Table 5 shows the expression rates of the polymorphic variants of the CVP.M VWco/
and CVPJMI/Msp/ sites in patients with HNSCC, BHNL patients and healthy blood do-
nors. The expression rates of the different polymorphic variants were not statistically
significant between the different groups. Presence of the rare G (valine) allele in the
Ncol site ranges from 16.4% in the blood donor group to 25.6% in BHNL patients. In
the Mspl site the rare C nucleotide occurred approximately equally frequent as the rare
allele in the Ncol site and ranges from 15.4% in BHNL patients to 17.8% in HNSCC pa-
tients. Chi square analyses gave p-values of 0.7114 and 0.9561 when comparing
HNSCC or BHNL with blood donors, and here again no statistically significant differ-
ences could be found.
In the BHNL group, rare alleles in both the CyPl^J/Nco/ and CYP-Ml/Msp/ sites (Ta-
ble 5) were found in 7 (9.0%) cases, whereas a rare allele in only one of the sites was
found in 18 patients (23.1%) and no rare alleles in 53 patients (67.9%). In the HNSCC
group these percentages were 8.1, 20.0 and 71.9%, respectively. Finally, in the blood
donor group these rates were 7.2,17.9 and 74.9%, respectively. The balance between
the different polymorphic variants in the CYP1>*J/Msp/ and CYP1A 1/Nco/ sites was
significantly correlated in each population studied.
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Table 6. Distribution of potymorphic variants m CVPIAI/Neo» and CYP1AJ/M&P' Mas m patients «nth HNSCC BHNL
and in control«
r W
«CO/™'»
NcoT',*tapr'
NcoT*,««/*"
Neor'**,M»pr'
^«••'•.Msp/'"»
osrMi'.Mtpr*
GSTMl'.Mspr'*''
OSTW1 .Mipf"
OSfMl . M M / " »
HNSCC<%)
151 (81.6)
34(18.4)
152(82 2)
33(17.8)
1331719)
18(9.7)
19(10 3)
15(8.1)
78(42.2)
13(7.0)
74 (40 0)
20(10.8)
BHNL (%)
58(74.4)
20 (25.6)
66(84 6)
12(15.4)
53(67.9)
5 (6.4)
13(16.7)
7 (9.0)
40 (51.3)
1(13)
26(33 3)
11(14.1)
Controls (%)
173 (83.6)
34 (16.4)
174(84.1)
33(15 9)
155(74.9)
19 (9.2)
18(18.7)
15(7.2)
84 (40.6)
16(77)
90(43 5)
17 (8.2)
" , wild type; '"•. rare allele present
Combining polymorphic expressions of GSTM1 and CVPl/^J/Wsp/, GS7T1 and
CVPIAI/Msp/ or GS7T1 and CyPlAl/Nco/ only showed one statistically significant dif-
ference: The GS7M1 nu// genotype and a rare allele in the CYPIAI/Msp/ site occurs
more frequently in patients with BHNL than in blood donors (X^-8.8, p=0.03).
Discussion
Extensive consumption of tobacco and/or alcohol are regarded as risk factors for head
and neck cancer (1-5). Tobacco smoke contains several (pre)carcinogenic com-
pounds. Enzymes such as GSTM1, GSTT1 and CYP1A1 are involved in the metabolism
of several of these chemical (pre)carcinogens. In the assessment of individual cancer
risk the identification of heritable variations in the expression of these enzymes, which
could predispose subjects to such environmentally induced cancer, deserve consider-
able interest. GS7M1 shows a polymorphic expression and about half the population in
various racial groups is deficient of the GSFMl gene (14). Because the GSTM1 enzyme
can detoxify potential carcinogens like epoxides and aromatic hydrocarbons from
tobacco smoke (13), smokers lacking GSTM1 activity were suggested to be at high risk
of developing lung cancer (17). The GS7M1 ni/// genotype was associated with high
risk for lung, bladder, gastric, colorectal, skin, head and neck, and larynx cancer in sev-
eral recent articles (18-26,54,55). However, other data were presented in which no
contribution of the GSTM1 nu// genotype for cancer risk was found (29,35,56-60).
Our data on the GSr/Vfl nu/7 genotype in patients with HNSCC were in agreement with
the latter reports. We found no difference in GSr/Vfl gene expression between patients
with HNSCC or BHNL and healthy blood donors. In the HNSCC subgroups of patients
with larynx or oral-oropharynx tumors, no differences could be observed either. There-
fore, GS77W1 polymorphism does not seem to influence the susceptibility for BHNL or
HNSCC in the total group or in subgroups of larynx and oral-oropharynx carcinoma. This
suggests that presumed carcinogenic or toxic compounds causing either of these le-
sions are detoxified by enzymes other than GSTM1.
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In addition, the recently discovered polymorphism of GS7T1. which is a result from a
gene deletion (33) was investigated by PCR. The GS7T1 nu// genotype was found to be
related to increased colorectal and larynx cancer susceptibility (56,57). whereas other
reports found no relationship between GSTTi nt/// genotype and lung, oral and gastric
cancer, and cutaneous basal cell carcinoma (35.56,58). However, no higher incidence
of GS7T1 nu» genotype in benign lesions was reported before. We demonstrated an in-
crease in GS7T1 nu// genotypes in patients with BHNL as compared to blood donors
and patients with HNSCC. In the HNSCC subgroups as well as the total group of pa-
tients with HNSCC the ni/// genotype frequency equalled that of the blood donor group.
This suggests that GS7T1 deficiency indicates an increased risk for BHNL. but not for
HNSCC. This could implicate that BHNL and HNSCC may be caused by different me-
chanisms, and possibly one of the factors involved in BHNL may be a substrate for the
GSTTI enzyme.
Because Chevenix-Trench et al. (54) recently suggested a trend of lower percentage of
GS7T1 nu// genotypes in geriatric controls versus unselected (and most probably youn-
ger) controls, we looked for the same tendency in our control population. Thus, the
control group was split up into two age groups (below 40 years and 40 years and
above). We could not find a difference in the distribution of GSTTI nu// genotypes be-
tween these two groups and a percentage of 24% nu// genotypes was found in the age
group of 40 years and above. In addition, because in our study the number of GS7T1
nuff individuals in healthy volunteers matched very well with both data in the literature
(12,54) and the frequencies found in patients with HNSCC, we believe the age diffe-
rence between controls and patients may not be of any consequence for the genetic
analyses as performed here.
Combined analysis of GST7W1 and GS7T1 polymorphisms demonstrated a statistically
significant impact on head and neck carcinogenesis. It has previously been shown that
combined GSTM1 and GSTTI nu// genotype was related to lung cancer risk (35). No re-
lation, however, between GSTTvfl and GSTTI nu// genotype and multiple cutaneous
basal cell carcinoma (32) was found.
In addition to polymorphisms in phase II enzymes, genetic polymorphisms in the phase
I enzyme CVP1A1 gene were correlated to an increased susceptibility to chemical
carcinogenesis (37,39,44,46-48). The CYP1A1 enzyme is involved in the activation of
benzo[ajpyrene and other aromatic hydrocarbons in tobacco smoke (36-42). Genetic
variants in the CVP1A1 gene investigated here can result in an enhancement of the
CYP1A1 enzyme activities (43,45). We demonstrated no difference in the distribution
of genetic variants of the CVPIAI/Nco/ nor of the CYP1A1/Msp/ site between patients
with HNSCC, BHNL and blood donors, suggesting that these variations do not have a
significant impact on the risk for these head and neck lesions and that compounds
causing these lesions may not be activated by this enzyme. The Msp/ polymorphism of
the CVP1A1 gene was associated with a reduced survival in patients with non-small
cell lung cancer (59). It was also an independent factor indicative for bad prognosis at
the nonresectable advanced stage of this disease (59). In bladder cancer and
squamous cell cancer of the lung, however, no impact of CYP1A1/Msp/ variants on
cancer susceptibility was found. Genetic variation in the CYPIAI/Nco/ site was weakly
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but nonsignrficantly associated with enhanced postmenopausal breast cancer risk
(29), whereas another study reported a stronger association (30).
Individually, presence of the rare allele in the CVP1A VWsp/ site or a GSfMl nu// geno-
type had no effect on the development of squamous or small cell carcinoma of the lung
(31). Combined, however, they were significant risk factors (p<0.01) (31). We now
found that having both GSFMl nu// genotype and a rare allele in the CVPIAJ/Wsp/ site
had a significant impact on the risk of BHNL as compared to blood donors. This
strongly suggests that generation of reactive metabolites by the CYPlAl enzyme and
subsequent lack of detoxification by the GSTMl enzyme may be of importance in the
etiology of BHNL. Several other studies showed comparable results with respect to
combined polymorphisms and increased risk for development of malignancies. Combi-
nation of GSTM1 r>u// genotype and the rare CYPIAI/Msp/ allele showed an increased
risk of squamous cell carcinoma of the lung when diagnosed before 66 years of age
(61), and patients with non-small lung cell cancer carrying this combination of
polymorphisms had remarkable shortened survival (59). The interactive effect of
GSr/vfl and CYPlAl genotypes (45) suggests that the influence of detoxifying en-
zymes in mediating cancer risk may be modified by polymorphisms at other relevant
loci as well. This is an important point which needs further attention in the future.
In summary, our study shows that (a) GS7T1 ni/// genotype is a risk factor for BHNL, but
not for HNSCC, and (b) combined GS77W1 nu// genotype and a rare C nucleotide in the
CYPl/U/Msp/ site was more often detected in patients with BHNL as compared to
blood donors, but not in patients with HNSCC.
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Abstract
Background We compared the GSTM1, GS7T1 and GSTP1 genotype frequencies in
two groups of healthy blood donors, recruited from different, but neighboring regions
in the Netherlands. The effect of cross linked comparisons for head and neck squa-
mous cell carcinoma (HNSCC) on the outcome of a study previously published in Can-
cer is analysed.
Methods The GS7M1, GSTT1 and GSTP1 genotype frequencies in two Dutch Caucasi-
an control populations (n-207 and n-285) from different but neighboring geographi-
cal regions (Maastricht/Nijmegen; distance, 125 km) were determined by polymerase
chain reaction (PCR) related methods.
Results For the occurrence of the GSTT1 nu// genotype we found a significant differ-
ence (P"0.003) between the two control groups (20.3% vs. 33.0% nt/// genotype in the
Nljmeflen and Maastricht control groups, respectively). Since the HNSCC patients are re-
cruited from the Maastricht area, comparison with the Maastricht controls now reveals a
significant difference for GS7T1 nu/f rates, which are lower in patients vs. controls
(OR-0.49, Cl 0.32-0.76).
Conclusions Inter regional differences exist, which may have significant effect in the
find that the GS7T1 nu// genotype appears to be involved in modulating the risk for
HNSCC. The significance of the distribution patterns of GST polymorphisms in head
and neck cancer patient populations can only be analyzed in comparison to a regional
control group.
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Introduction
In 1998 we investigated genetic polymorphisms in glutathione S-transferase M l
(GS7M1) and GS7T1 in relation to head and neck squamous cell carcinoma (HNSCC)
(1). In this study we reported that GSTM1 and GS7T1 nu// genotypes were not related
to HNSCC susceptibility, but that the GS7T1 nu// genotype occurred significantly more
often in a patient population with benign head and neck lesions (BHNL). We therefore
concluded that the GS7T1 nu// genotype was not a risk factor for HNSCC, but may be a
risk factor for development of benign head and neck disease.
In this collaborative study between the University Hospitals of Nijmegen and
Maastricht, the GST polymorphisms in healthy blood donors from the Nijmegen region
were compared to patients with HNSCC from the Maastricht region. Since these two
cities are separated geographically by only 125 km, we did not expect that significant
differences in variant GSI genotype rates could occur between two study groups origi-
nating from such close regions.
There have appeared many conflicting reports on the contribution of genetic
polymorphisms in GSTs, in association with head and neck cancer or other malignan-
cies, which may be partly due to mismatching of patient- and control populations.
Therefore, we now compared the variant genotype frequencies of GSTM1, GSTP1 and
GS7T1 in the control population of Nijmegen and a recently established control popu-
lation of the Maastricht region. Also, we investigated whether these new data have any
effect on our previously published results (1).
Materials and Methods
Populations studied
The first Dutch Caucasian control group (control group Nijmegen) consisted of 207
healthy blood donors (76 men; 131 women) and was recruited as described before (1)
by advertising in a local paper at the University Medical Center Nijmegen (mean age 34
± 12 years; range 19 • 64). A second Dutch Caucasian control group (control group
Maastricht) consisted of 285 healthy blood donors (199 men. 86 women; mean age
50 ± 10 years; range 19 - 91) and was recruited from the same geographical area as
the HNSCC and BHNL patients, at the Blood Bank of Maastricht. The geographical dis-
tance between the two cities Nijmegen and Maastricht is approximately 125 km. An
extra control population (control group BHNL) consisted of 78 patients (mean age 49 ±
16 years; range 16 - 86) with benign head and neck lesions (BHNL) such as polyps,
cysts, and vocal cord nodules, as described before (1).
The 185 Dutch Caucasian patients with HNSCC participating in the initial study (1)
were recruited preoperatively or postoperatively as described previously during their
scheduled outpatient visit at the University Hospital Maastricht between 1994 and
1996 (mean age 60 ± 12 years; range 23 - 86). This group consisted of 73 patients
with laryngeal carcinoma (mean age 62 ± 11 years; range 36 - 86), 76 patients with
43
oral and oropharyngeal carcinoma (mean age 58 ± 12 years; range 23 - 82) and a re-
maining group of 36 patients (mean age 60 ± 13 years; range 28 - 86).
At the time when informed consent was obtained, medical and other anamnestic data
were obtained by interview. The investigations were approved by both the Nijmegen
and Maastricht local Medical Ethical Review Committees.
Genotyping by PCR Analyses
Blood was collected by venapuncture in EDTA vacutainer tubes, and blood was stored
at -20'C until use. Genomic DNA was isolated from whole blood using the Wizzard
genomic DNA isolation kit, according to the instructions of the manufacturer
(Promega. Madison Wisconsin, USA). Genetic polymorphism rates were determined by
Initial PCR, followed by analysis on agarose gel.
Fifty to hundred ng of DNA were amplified by PCR in a total volume of 25 pi containing
10 mM Tris/HCI pH 9.0, 50 mM KCI, 0.1% Triton X-100. 2 mM MgCI?. 200 uM of
deoxynucleotide triphosphate, 1 uM of each primer, and 0.2 units of Taq polymerase,
overlaid with one drop of mineral oil. PCR was carried out in a programmable
Thermojet thermocycler (Eurogentec, Seraing, Belgium). After 5 min of pretreatment
at 95"C. 35 cycles of 30 sec denaturation at 95°C and 30 sec annealing at 59°C were
performed. All primers were selected based on studies by others (2-4). The primers
were synthesized by Pharmacia Biotech (Roosendaal, The Netherlands). All chemicals
needed for PCR were purchased from Promega (USA). For GSTM1 (primer set G2 and
G3) and GS7T1 (primer set T l and T2) one primer was situated in the deleted area. For
evaluating GS77W1 and GS7T1 polymorphisms, reaction mixture products were ana-
lyzed by gel electrophoresis (2% agarose; 60 V; 1 h) for the presence of a 650-base
pair product, which was indicative of the GSTM1 gene or a 480-base pair product, in-
dicative of the GS7T1 gene. When at first analysis no product was found, always a sec-
ond and eventually a third analysis was done, in parallel with a control PCR from the
same DNA samples, so that a false negative result (apparent nu// genotype) was ex-
cluded. For studying the genetic polymorphism in GSTP1 a primer set (105F and
105R) was designed so that the presence of the A to G substitution at codon 313 re-
sulted in the appearance of an Alw261 restriction enzyme site (4).
Stat is t ical analysis
Statistical analysis was performed by using the SPSS 8.0 statistical package. Odds Ra-
tio analyses in 2x2 tables were used, as well as calculation of p-values.
Results
In Table 1 the frequencies of GSfMl and GS7T1 genotypes of the two different normal
control populations from Nijmegen and Maasticht are shown. The GST/vfl and GS7T1
genotypes of the group of patients with HNSCC and BHNL from the Maastricht region
are included. For the GSTM1 genotype, both control groups compared to each other,
and the HNSCC patient group compared to the frequencies of the control groups from
Nijmegen and Maastricht show no statistical difference (see Table 2).
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The genotype frequencies for GS7T1 however, show a significant difference between
the two control groups from Nijmegen and Maastricht (p»0.003). The BHNL group
shows a frequency that matches the control group Maastricht.
For GS7P1 there are no statistical differences between the two control groups from
Nijmegen and Maastricht.
Table 2 shows risk estimates for the susceptibility of the various GSrMl and GS7T1
genotypes on HNSCC when compared to different control groups. For the GSTP1 geno-
type only a risk estimate is shown when compared to the two control groups. For
GSIM1 and GSfPl genotypes no significant differences were found. For the GS7T1 ge-
notype however, a significant difference was noted when the risk for HNSCC is esti-
mated versus control group Maastricht, which matches with the patients with respect
to recruiting area and race (p=0.002).
TaMe 1. Frequencies of GSTM1 and GSJT1 genotypes in the different control population» and in patient« with BHNL
and HNSCC
GSTM1 (null)
GSTM1*
GSI71 (nuW)
Gsm*
GSrPl AB
GSTPl 8B
GSTP1 AA
Controls
Nijmegen (%)
107(51.7)
100(48 3)
42(20.3)
165(79 7)
88 (43 6)
25(12 4)
89 (44.0)
Controls
Maastricht (%)
163(57.2)
122(42.8)
94 (33.0)
191(67.0)
122 (42 8)
37(12.9)
126(44.2).
BHNL
Maastricht (%)
37(47.4)
41(52 6)
26(33 31
52(66.7)
1
1
«
HNSCC
Maastricht (%)
94 150.8)
91 (49 2)
36(19 5)
149 (80S)
1
1
•
Total 207(202* ) 285 78 185
* - controls for GSTP1 (five DNA samples were not available any more), * - not evaluated
TaMe 2. Risk estimate of GSTM1. GS7T1 and GSTP1 genotype frequencies compared in two different control populatl
ons and HNSCC patients
GSTM1 nuW
Control Maastricht vs. control Nijmegen
HNSCC vs Nijmegen
HNSCC vs Maastricht
GS7TI null
Control Maastricht vs. control Nijmegen
HNSCC vs Nijmegen
HNSCC vs Maastricht
Odds Ratio (95% CO
1.25(0.86-178)
0.96(0 65 1431
0 78(0.5*1 12)
192U2&2 94)
0.95 i0.57 1.56)
0 49(0 32-0 76)
P
0.26
0 94
0 21
0003
094
0002
GSTPl AB/BB
Control Maastricht vs control Nijmegen 1.00 (0.69-1.43) 0.97
* - Odds Rat» was calculated by combining GSTP1 AB and GSTPI SB genotype*
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Discussion
In this study we found a highly significant difference in the rates of the GS7T1 nu// ge-
notype between controls from the Nijmegen and Maastricht region. This has conse-
quences for the interpretation of earlier results reported by us in 1998 (1), since now a
significant lower risk for HNSCC of individuals with the GS7T1 nu// genotype is found.
First of all, how can such inter-regional difference between controls be explained?
Most probably the tendency to stay in the region of birth, may be a main reason, since
it is well known that genetic inheritance contributes to the genetic profile of an
individual.
Most studies that have been conducted on the role of polymorphisms in modulating
the risk for HNSCC, do describe demographical data (see Table 3), with the exception
of some papers (5 8) where no details on this are given. This does not mean however
that demographic variation is present here. In several studies it is clearly mentioned
that patients and controls were recruited from the same region, but not from the same
hospital (9 12), thus similar to our earlier study (1). In other studies it was mentioned
that patients and controls were recruited from different regions (1.13,14). Since there
are many national and international collaborations between the different research
groups with exchange of samples between different labs, it may often occur that con-
trols and patients have been recruited from different (parts of) countries, which may
have similar consequences as described in this paper.
Recently in a large international collaborative study Garte et al. (15) reported signifi-
cant differences between different racial populations for GSTM1 and GS7T1 geno-
types. For the GS77VJ1 nu// genotype, frequencies found were 53.1% for Caucasians,
52.9% for Asians and 26.7% for Africans. The total number of African patients included
however, was only 4% (479 individuals) on a total number of 12,504 patients evalu-
ated. For the GS7T1 nu// genotype, the frequencies for Caucasians were 19.7% com-
pared to 47.0% for Asians (15).
Garte et al. (15) reported considerable differences in GSTM1 and GS7T1 genotype fre-
quencies in Caucasian populations of several European countries, Canada or the USA
(47-58% and 13-27% for nu// genotypes respectively). These findings suggest that
these frequencies are rather variable in Caucasians all over the world. In addition, the
data on GS7T1 nu// genotype frequency as found in our controls from the Maastricht
region (33%) seem to be higher as compared to earlier reported data from European
countries (13-26%) and are closer to those reported in the USA (27%) or Japan (35%)
(15).
For the GS7T1 genotype we found an unexpected significant difference (p=0.003) be-
tween the two Dutch control groups, collected at a distance of approximately 125 km.
In our earlier report we even suggested a possible role for GS7T1 genotype in the
etiology of BHNL (1).
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Table 3. Demographics of control and HNSCC patient populations and GS7T1 nuH genotype frequencies
Site GS771 nuH GSTT1 nuH RaceAuthor
Controls
% (n-total)
Cases
% (n-total)
Country Same demographics
patients-controls
Odds Ratio (95% C1)
No association CSTT1 nu«
genotype vs. HNSCC
Buchetal. (17)
Cabelguenne et al. (18)
Deakinetal. (19)
Hanna et al (7)
Hong el al. (20)
Hung et al (21)
Jourenkova et al. (22)
Jourenkova et al. (23)
Katohetal. (24)
Matthias et al. (25)
MeWilliams et al. (26)
Otsnanetal (27)
Oude Ophus et al. (1)
Sreeiekha et al. (8)
Truna et al. (30)
Worral et al. (28<
Association GSITI nu»
(•notyp* vs HNSCC
Cnengetal. i l4 )
Harriet et al. (29)
Jahnke et al. |5.6)
Jourenkova et al. (23)
Oral
HN
Oral
Larynx
Larynx
Oral
Larynx
Pharynx
Oral
Larynx
Oropharynx
HN
HN
HN
HN
Oral/oropnarynx
Larynx
Oral
HN
Oral
HN
HN
Larynx
Oral
HN
Oude Ophus et al. (this arude) HN
12.3 (450)
19.4 (264)
18.5(129)
20.0 (20)
36.5 (63)
52.9(123)
15.7(172)
15.7(172)
51.0(147)
22.2 (203)
22.2 (203)
22.2 (203)
18.3(109)
13.0(168)
20.3 (207)
20.3(207)
20.3 (207)
8.3 (60)
36.0 (42)
n.s.
17.5(315)
20.0(101)
12.4(145)
15.7(172)
15.7(172)
33.0 (285)
18.3 (297)
18.1 (162)
11.8 (34)
15.0 (20)
57.3(82)
58.5(41)
19.4(129)
18.0(50)
47.7(92)
19.4 (263)
27.7(119)
22.0 (382)
•16.9(142)
17.0(109)
19 5(185)
19.7(76)
20.5(73)
18.4 (98)
45.0(186)
n.s.
32.7 (162)
9.0(70)
21.3(169)
22.4 (67)
21.5(121)
19.5(185!
Indian
n.s.
Caucasian
n.s.
Korean
Chinese mixed
Caucasian
Caucasian
Japanese
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Caucasian
Indian
Mixed
Caucasian
Mixed
Mixed
Caucasian
Caucasian
Caucasian
India
France
UK
USA
Korea
Taiwan
France
France
Japan
German
German
German
USA
USA
The Netherlands
The Netherlands
The Netherlands
India
USA
UK
USA
Germany
France
France
The Netherlands
yes
yes
yes
n.s
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
no
no
no
ni
yes
yes
no
ves
riA
yes
yes
yes
1.6(1.0-2.6)
1.0(0.6-1.7)
n.s.
n.s.
1.8(0.7-4.8)
1.2 (0.6-2.5)
1.4 (0.7-2.9)
1.4 (0.6-3.7)
0.7 (0.4-1.2)
0.9 (0.5-1.4)
1.5 (0.9-2.5)
n.s.
0.9(0.5-1.5)
1.4 (0.7-2.7)
1.1(0.6-1.7)
1.0 (0.5-2.0)
1.0(0.5-1.9)
2.5 (0.3-21.7)
1.5 (0.7-3.0)
nj.
2.3(1.4-3.6)
2.5 (1.1-5.9)
nj.
2 4(1.0-5.5)
2.0(1.0-4.0)
2.0(1.3-3.2)
n.s. not specified, n- total number of patients or controls in group. HN - a l sites of head and neck n « * » iimc « I . d - confidence Wervai
However, when the risk for HNSCC is estimated versus the new control group, we
found a significant reverse association between GS7T1 nu// genotype and HNSCC
(OR-0.49, Cl 0.32-0.76, p-0.002). We did not expect to find a difference in genotype
frequency between such close regions, especially since the Netherlands is a very small
country. Earlier, Roy et al. (16) found GS7T1 nu// genotype frequencies ranging from
3-39% in different Indian ethnic populations. They, however, did not mention distance,
which may be much larger since India is a large country. In our study the different
results can not be explained by ethnicity, since in The Netherlands geographically con-
fined ethnic variations do not exist. We also can not explain this by a misinterpretation
of PCR results, since the lack of an amplification product was always tested three
times.
The association of genetic polymorphisms In toxification / detoxification enzymes and
HNSCC Is still a matter of controverse (see Table 3). We now have shown that signifi-
cant demographic variations in genotype frequencies may exist, even in a small coun-
try. Demographic variations may be the key solution in explaining the differences in
outcome in genetic polymorphism studies. In contrast to our earlier conclusion (1), we
now must conclude that the GS7T1 nu// genotype appears to be less common in pa-
tients with HNSCC. A similar finding was published recently by London et al. (31) who
found lower GSTM1 and GS7T1 nu/J genotype rates in patients with lung cancer, as
compared to age and location matched controls. The authors could explain this finding
as follows: consumption of cruciferous vegetables may protect against smoking in-
duced cancers by their content of glucosinolates, precursors of isothiocyanates, the
latter being potent inducers of glutathione S-transferases and other detoxification sys-
tems. However, since breakdown of isothiocyanates is also catalysed by GSfs, GS7T1
and/or GS77W1 nu// individuals may have a worse clearance of isothiocyanates and
may be better protected when consuming glucosinolate containing diets.
In conclusion: in contrast to the hypothesis that GS7T1 nu// genotype occurs more in
patients with HNSCC we found the opposite; a less frequent occurrence of GS7T1 nu//
genotype in HNSCC patients.
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Abstract
Background Many tumors contain high amounts of the detoxification enzyme glutat-
hione S-transferase Pl-1 (GSTP1-1). Elevated levels of GSTP1-1 have also been detec-
ted in serum and plasma from patients with gastrointestinal, lung or head and neck
tumors. We evaluated the role of GSTP1-1 as a plasma tumor marker in patients with
larynx-hypopharynx-oropharynx sites of head and neck squamous cell carcinoma
(HNSCC). and benign head and neck lesions (BHNL).
Methods GSTP1-1 levels were measured in EDTA plasma using a recently developed
sensitive and specific sandwich ELISA. An upper normal reference level of 21.8 ug
GSTP1 1 per liter of plasma was calculated from results obtained from samples of 230
blood donors.
Results Median GSTP1-1 levels of 53 patients with oral/oropharyngeal SCC (10.6
yg/L: range 3.7-46.1 ug/L). 12 patients with hypopharyngeal SCC (11.9 ug/L; range
5.2 146.6 pg/L) and 28 patients with laryngeal SCC (14.4 ug/L; range 6.4-141.5
ug/L) were significantly elevated when compared to plasma GSTP1-1 levels from 45
patients with BHNL (8.1 ug/L; range 3.3-32.3 ug/L, P<0.0001. P<0.01 and P<0.0001
respectively). However, only 6/53 patients (11%) with oral/oropharyngeal SCC. 1/12
patients (8%) with hypopharyngeal SCC. and 6/28 patients (21%) with laryngeal SCC
had plasma GSTP1-1 levels above the upper normal reference level. Thus overall only
13/93 patients (14%) with HNSCC had elevated plasma GSTP1-1 levels. No significant
relation between plasma GSTP1-1 levels and TNM classification of the tumors was
detected.
Conclusions GSTP1-1 is not a suitable plasma tumor marker for HNSCC.
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Introduction
Glutathione S-transferases (GSTs) are enzymes that catalyze the addition of
glutathione to electrophillic centers of a wide variety of compounds. This reaction is
the first step in the formation of mercapturic acids, a pathway mostly resulting in the
elimination of potentially toxic compounds. GSTs also serve as transport proteins for a
broad range of lipophillic compounds, such as bilirubin, bile acids, steroid hormones,
and various xenobiotics (1,2). Based on structural, physiochemical. enzymatic, and im-
munological properties the family of enzymes is divided into four classes: Alpha, Mu, Pi
and Theta (1-4).
Malignancies from colon, stomach, urinary bladder, uterine cervix, lung and larynx of-
ten contain increased amounts of GSTP1-1 when compared to the adjacent normal tis-
sue (5,6). Three studies published in 1989 all indicated that a considerable number of
patients with gastrointestinal malignancies had elevated serum GSTP1-1 levels (7-9).
Hirata et al. reported elevated plasma GSTP1-1 levels in 41 /61 patients (76%) with
primary oral cancer (10). These authors also reported an impressive decline in plasma
GSTP1-1 levels after surgical resection of the tumor: 16 of 25 patients (64%) with good
prognoses had elevated GSTP1-1 levels before surgery and all values normalized
within eight weeks post-operatively. High GSTP1-1 levels were not only reported in
plasma; immunohistochemical investigations also showed increased levels of
GSTP1-1 in head and neck tumor tissue, which decreased after radiation therapy (11).
Because blood cells and platelets contain large amounts of GSTP1-1, the sampling
procedures for serum or plasma are exceptionally critical (12-14). We recently re-
ported that plasma samples had to be collected in special silicone coated ethylene
diamine tetra-acetic acid (EDTA) blood collection tubes and should be processed un-
der strict conditions to avoid spuriously high plasma GSTP1-1 levels (14).
In the current study, we investigated plasma GSTP1-1 levels in blood samples from pa-
tients with head and neck squamous cell carcinoma (HNSCC) and benign head and
neck lesions (BHNL).
Materials and methods
Patients
All blood samples from patients were collected at the Department of Otorhinolaryn-
gology. Head and Neck Surgery, University Hospital Maastricht, the Netherlands. 53
patients with oral/oropharyngeal SCC, 12 patients with hypopharyngeal SCC and 28
patients with laryngeal SCC were studied. All diagnoses were confirmed by histology.
Tumors were staged according to the TNM regulation of the International Union
Against Cancer (15). The median age of the 93 HNSCC patients was 59 years (range
23-82 years) and 70 patients (75%) were males. Forty five patients with BHNL were
studied (7 patients with parotic pleomorphic adenoma, 6 patients with submandibular
disorders, 12 patients with rhinological disorders. 12 patients with vocal cord disor-
ders, and 8 patients with neck disorders). The median age of this BHNL group was 47
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years (range 16-86 years) and 26 patients (58%) were males. Patients with hepatic
disorders were excluded from the study. As a control group served 230 blood donors,
median age 35 years (range 18-69 years).
This study was approved by the local Medical Ethical Review Committee.
Plasma samples
Approximately 3 ml of blood was collected by venapuncture in vacuumed, silicone
coated, K3 EDTA containing tubes (Vacutainer, order no. 606601 Becton Dickinson,
Grenoble, France). Immediately after collection of the sample, blood was gently mixed
with the EDTA solution. Tubes were centrifuged for 10 minutes at 3000 x g at room
temperature within 2 hours. The upper two-third part of the plasma was collected and
care was taken not to aspirate the platelets on top of the cell layer. Plasma samples
were stored in portions at -20°C.
Assays
Plasma GSTP1-1 concentration was measured using a recently developed enzyme
linked immuno assay (ELISA) (14). Briefly, microtiter plates were coated overnight with
purified antl-GSTPl-1 monoclonal antibody. One hundred uL of standard (0.4-100
ug/L GSTP1-1). or 1:1 diluted plasma samples were added to the wells and incubated
overnight. The next day the plates were washed and incubated with rabbit
antl GSTP1 1 serum, washed again, incubated with horseradish peroxidase labeled
swine anti-rabbit and after a final wash, plates were stained with o-phenyl-
enediamine-HjOj. Standards and samples were measured in duplicate. A four param-
eter weighted logistic regression model was used to calculate standard curves and
unknowns. The assay had no cross reactivity with GSTs of the Alpha or the Mu classes;
the detection limit was 0.4 ug/L GSTP1-1 and the intra- and inter-assay coefficients of
variation were 5.8% and 10.9%, respectively.
Calculations and statistics
Plasma samples were categorized according to whether their GSTP1-1 content was
below (normal) or above (elevated) the upper limit of the normal reference level. An up-
per normal reference limit of 21.8 ug/L GSTP1-1 was calculated from plasma samples
of the 230 healthy blood donors (14).
The statistical significance of differences between groups of patients and healthy con-
trols was evaluated using the two-tailed Wilcoxon's rank-sum test. To avoid spurious
differences, data were initially subjected to a Kruskal-Wallis analysis. All statistical
analyses were performed using SPSS/PC+ statistical computer software version 5.0.
GSTP1-1 levels are expressed as medians with ranges, unless stated otherwise.
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Results
The median GSTP1-1 levels for 53 patients with oral/oropharyngeal SCC (10.6 pg/L;
3.7-46.1 Mg/L). 12 patients with hypopharyngeal SCC (11.9 Mg/L; 5.2-146.6 Mg/L) and
28 patients with laryngeal SCC (14.4 pg/L: 6.4-141.5 pg/L) were significantly elevated
when compared to the median plasma GSTP1-1 levels for 45 BHNL patients (8.1 Mg/L;
3.3-32.3 Mg/L: P<0.0001, P<0.01 and P<0.0001, respectively). The median plasma
GSTP1-1 levels for these three groups of patients with SCC were also significantly ele-
vated when compared with the median plasma GSTP1-1 levels for 230 healthy con-
trols (7.2 pg/L; 2.2-71.6 pg/L) (P<0.0001, P<0.007 and P<0.001, respectively).
However, plasma GSTP1-1 levels were above the upper limit of the normal reference
level in only 6 of 53 patients (11%) with oral/oropharyngeal SCC, 1 of 12 patients (8%)
with hypopharyngeal SCC and in 6 of 28 patients (21%) with laryngeal SCC (Figure 1).
Overall 13 of 93 patients (14%) with HNSCC had elevated plasma GSTP1-1 levels,
whereas only 1 of 45 patients (2.2%) with BHNL had an elevated plasma GSTP1-1 level
(Figure 1). Plasma GSTP11 levels were not related to TNM stage grouping of the tu-
mors (Table 1). Patients with HNSCC were significantly older than patients with BHNL
(median 59 years, range 23-82 years and median 47 years, range 16-86 years,
respectively; P< 0.002).
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Figure 1. Plasma glutathione S-transferase PI 1 (GSTP11) levels in patients with head and neck
squamous cell carcinoma and patients with benign head and neck disorders. The dashed line denote«
the upper normal reference limit.
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TaMe 1 . Plasma glutathione S4rsnefenee P l - 1 (GSTPl-1) levels in patients with head and neck squamous cell carci-
noma according to stage of disease.
TNM Plasma GSTPl-1 (ugA) median (range)
Stage (number of patients)
Oral/oropharyngeal SCC Hypopnaryngeal SCC LaryngealSCC All sites HNSCC
1
N
M
rv
9.3 (5.4 22.1)
(9)
9.4 (6.6-22.1)
(12)
10.8(4.6-46.1)
111)
10.9(3.730.5)
(20)
Differences between TNM tea»
(0)
10.8(9.5-12.1)
(2)
12.9(12.0-13.8)
(2)
10.7 (5.2-24.2)
(8)
ffouoms were not significant
14.6(8.^30.1)
(6)
17.6(6.4-141.5)
(6)
14.0
(1)
11.7(6.6-94.9)
(13)
. From one Datiert with an i
11.8(5.4-30.1)
(15)
9.6(6.4-141.5)
(20)
11.2(4.6-46.1)
(14)
11.1(3.7-94.9)
(41)
oral/orooharvniteal tt
and from two patients with leryngeel tumor* the TNM classification and stage was not recorded.
Discussion
The ideal tumor marker is a tumor specific screening tool that assists in the workup
and follow up of oncologic patients. It can also monitor the response to therapy, in
which case it should be directly related to tumor bulk or tumor load. By these means,
the marker should be able to detect tumor recurrence and/or regional or distant
metastases before clinical presentation.
Hirata et al. reported elevated plasma GSTPl-1 levels in 41 of 61 patients (76%) with
primary oral cancer and normal GSTPl-1 levels in patients with benign oral disease
(10). These authors also reported an impressive decline in plasma GSTPl-1 levels af-
ter surgical resection of the tumor: 16 of 25 patients (64%) with good prognoses had
elevated GSTPl-1 levels before surgery and all values normalized within eight weeks
postoperatively. They also detected elevated plasma GSTPl-1 levels in most patients
with tumor recurrence after surgery, even before this recurrence was detected
clinically.
Because blood cells and platelets contain large amounts of GSTPl-1, the sampling
procedures for serum or plasma are exceptionally critical (1,2,13,14,16). Recently we
reported that even minor variations in the type of blood collection tubes or in the proce-
dures used to handle and centrifuge the blood may substantially affect the resulting
GSTPl-1 levels (14). This implies the need for identical sampling procedures for pa-
tients and controls. In our study the sampling, handling, storage, and assay proce-
dures were identical for all patients and other donors.
Hirata et al. also reported that mean plasma GSTPl-1 levels were higher in patients
with more advanced stages of SCC (10). More than 70% of patients with Stage III or IV
oral cancer, in contrast to approximately 50% of those with Stage I and II disease, had
elevated levels of GSTPl-1 in plasma. Niitsu et al. described elevated serum GSTPl-1
in more than 80% of patients with Stage III or IV gastric cancer, as opposed to only
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about 50% of patients with Stage I and II (9). We could not confirm this relation in a
larger group of patients (Hirata et al. (10) n - 61 , Niitsu et al. (9) n - 52; this study
n = 93). Median plasma GSTP1-1 levels were not significantly different among patients
with Stage I, II. Ill or IV HNSCC. Furthermore, when median GSTP1-1 plasma levels
were compared among tumor sites (oral-oropharynx, hypopharynx. larynx) and tumor
stages, no significant differences were found (Table 1).
In most earlier studies, no differences in serum or plasma GSTP1-1 levels between
males and females or among different age groups were observed (8-10,17,18). Vari-
ous serum GSTP1-1 cutoff levels have been reported by different authors. Upper nor-
mal reference limits of 3.7 ug/L, 15.4 ug/L, 34.0 ug/L, 34.8 ug/L GSTP1-1 in serum,
30.4 ug/L GSTP1-1 in heparin plasma and 5.4 ug/L and 13.99 ug/L in EDTA plasma
were reported in literature, based on samples from between 30 and 117 healthy con-
trols (7-10,13,17,18). In agreement with the results reported by Takahashi et al., our
control plasma GSTP1-1 levels also had to be log-transformed to obtain a nearly nor-
mal distribution (7). This transformation led to an upper normal reference level of 21.8
ug/L, as compared to a value of 21.9 ug/L, when calculated by taking mean value plus
2 times the standard deviation.
Our results also indicated that males had significantly higher GSTP1-1 levels than fe-
males. Among both males and females, a significant increase of GSTP1-1 levels was
noted with increasing age (14). Males ages 20-40 years, 40-60 years or older than 60
years had median plasma GSTP1-1 levels of 8.2 ug/L, 9.1 pg/L or 12.0 ug/L, respec-
tively. The values for females in the same age groups were 5.5 ug/L, 6.6 ug/L and 11.0
ug/L respectively (14). The group of 93 HNSCC patients comprised 70 males and 23
females. The HNSCC group was also significantly older than the group of patients with
benign head and neck disorders. These demographical variations may explain in part
the difference in plasma GSTP1-1 levels between HNSCC and BHNL or control groups.
Hirata et al. also reported that the reappearance of elevated levels of GSTP1-1 in
plasma occurred earlier than the clinical detection of recurrent disease in 10 of 13 pa-
tients with head and neck cancer (76.9%) (10). Several groups reported a decrease of
GSTP1-1 to normal levels after radical surgical resection of the tumor (9,10).
Because we found that a small minority of patients (14%) had elevated GSTP1-1 levels
in the diagnostic phase of our study, no collection of plasma for follow up studies was
performed.
Earlier we studied 20 patients with gastrointestinal carcinomas before and after
surgical resection of their tumors and found elevated plasma GSTP1-1 levels after re-
section of the tumor in some patients with normal preoperative levels (14). This indi-
cates that, in patients with gastrointestinal tumors a postoperative GSTP1-1 elevation
may well be caused by other mechanisms not related to tumorload. It is possible that
this also occurs in patients with HNSCC; however, further studies are needed to ascer-
tain this.
Perhaps manipulation of tumor and/or normal tissue may cause high intravascular
GST levels. When tumor or adjacent normal tissue contains a very high level of
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GSTP1-1, damage to these tissues during surgery could cause intravascular leakage
resulting in increased plasma levels postoperatively.
Elevated GSTP1-1 levels were found in patients with non-malignant hepatic disorders
(cirrhosis, hepatitis) suggesting that elevation of plasma or serum GSTP1-1 is not spe-
cific for malignant disease (8,9). In our study, patients were screened on hepatic disor-
ders by liver enzyme counts. Patients with high entries have been excluded for this
study. These criteria were not mentioned in most other reports.
In the current study, the clinical application of GSTP1-1 as a tumor marker for HNSCC
was evaluated. The levels of GSTP1-1 in HNSCC were significantly higher than the lev-
els in BHNL and control groups. However, only 13 of 93 patients with HNSCC demon-
strated elevated GSTP1 1 plasma levels. In contrast to earlier reports by others, we
conclude that GSTP1-1 can not be used as a tool for the diagnostic screening of
patients with HNSCC.
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Abstract
Background Factors determining the individual susceptibility to head and neck squa-
mous cell carcinoma (HNSCC) are still largely unknown. An imbalance between enzy-
mes involved in the toxification and detoxification of (pre)-carcinogens closely related
to HNSCC which may appear during smoking and alcohol consumption, may play a
role. Genetic polymorphisms in glutathione S-transferases (GSTs) often result in alte-
red detoxification, which may contribute to individual susceptibility to HNSCC.
Methods We studied the frequencies of polymorphic variants in the GSTP1 gene in
235 patients with HNSCC and 285 healthy controls. In addition, data on exposure to
alcohol and tobacco were recorded. DNA was extracted from whole blood and polyme-
rase chain reaction (PCR) based methods were used to detect genetic polymorphisms.
Ruiults In patients with HNSCC and control groups the homozygous GSfPl SS geno-
type was observed in 12.3% and 13.6% respectively. No statistical differences were
found for the GS7P1 A* and GSTP1A8/ GSTP1 86 genotypes.
Conclusions Our study showed that genetic polymorphisms of GSTP1 are not associa-
ted with altered susceptibility to HNSCC.
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Introduction
An imbalance in phase I drug metabolism enzymes such as cytochromes P450 (CYPs)
or phase II detoxification enzymes such as glutathione S-transferases (GSTs) may con-
tribute to the individual susceptibility to head and neck squamous cell carcinoma
(HNSCC). These enzymes, for instance, are involved in the toxification and detoxifica-
tion of metabolites of polycyclic aromatic hydrocarbons (PAHs), one of the primary car-
cinogens of tobacco smoke (1). Most PAHs first require activation by phase I enzymes
to become potential carcinogens that are subsequently detoxified by phase II
enzymes.
As a result of conjugation with glutathione, the potential carcinogens are eliminated
and DNA or other important biomolecules are protected against damage or adduct for-
mation (2-5). In humans, the GST enzymes can be divided into 5 main classes: Alpha
(GSTA). Mu (GSTM), Pi (GSTP), Theta (GSTT), and Zeta (GSTZ). Each class consists of
one or more iso-enzymes with different, but sometimes overlapping, substrate speci-
ficity (4,5). At present, genetic polymorphisms have been demonstrated for the
GSIMi, GS7T1, and GSfPl genes (5-9).
Polymorphisms in the GSTP1 gene consist of the variant genotypes GSTP1 AB and
GSfPl SB next to the wild type GS7P1 A4. The frequency of GSIP1 /M in healthy con-
trols ranges from 42 - 69% (9-14). A transition of Adenine (A) to Guanine (G) at nucleo-
tide 313 in exon 5 of the GS7P1 gene results in substitution of isoleucine (He) to valine
(Val) at position 104 in the amino acid sequence of the protein (7,15,16). The valine
variants exhibit lower specific activity and affinity for the electrophillic substrates of the
enzyme (7,13,15). The valine containing homozygous variant, GSTP1 SB, occurs in ap-
proximately 10 % of healthy controls, whereas the heterozygous Ile-Val variant, GSfPl
46, occurs in approximately 35% of controls (9-14).
The GSTP1 gene encodes for the iso-enzyme GSTPl-1. The GSTPl-1 enzyme level has
been extensively studied in relation to tobacco associated malignancies. The GSTPl-1
enzyme is overexpressed in many pre-neoplastic and neoplastic lesions. Elevated tis-
sue levels of GSTPl-1 enzyme have been found in stomach, colorectal, bladder, oral,
pharynx, larynx, lung, skin and breast tumors compared with normal tissues of
matched controls (5,17-22). The GSTPl-1 enzyme may be involved in the resistance to
chemotherapeutic agents and radiotherapy (5,23-25). Since GSTPl-1 is also involved
in the metabolism and subsequent removal of anti-cancer drugs, high levels of
GSTPl-1 in tumors may contribute to drug resistance in several different cancers
(26-28). However, there are also contradictory reports.
Because the amino acid change as result of the polymorphism close to the area of hy-
drophobic binding site for electrophiles, the homozygous GSfPl SB and heterozygous
GSTP1 4B gene products result in a decreased specific activity and affinity of the
GSTPl-1 enzyme for electrophillic compounds (7). Thus, the altered metabolic activity
of these enzymes could influence susceptibility to head and neck cancer. Earlier we in-
vestigated the possible involvement in HNSCC and in benign head and neck lesions
(BHNL) of genetic polymorphisms in CVPlvU, GSTM1 and GS7T1 but we found no en-
hanced rates of GST nu// genotypes in the cancer population (29). Earlier work from
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our group showed that the GSTP1-1 enzyme, in a quantitative sense, is by far the most
important detoxification enzyme in human head and neck tissues (30). Therefore we
now investigated genetic polymorphisms in the GSTP1 gene in a large series of pa-
tients with HNSCC and in matched healthy controls. We also evaluated exposure to al-
cohol and tobacco of these subjects and evaluated the potential effect modification
between GS7P1 polymorphisms and these environmental exposures.
Materials and Methods
Patients and controls
This case-control study was conducted in the patient referral region of Maastricht Uni-
versity Hospital. A total of 235 Caucasian patients (185 males, 50 females) with pri-
mary HNSCC were recruited during their scheduled admission at the Department of
Otolaryngology, Head and Neck Surgery of the University Hospital Maastricht between
1994 and 1998 (mean age 59 years; range 23-86 years). This group consists of 100
patients with larynx carcinoma (mean age 60 years; range 35-85 years), 114 patients
with oral cavity/oropharynx carcinoma (mean age 58 years; range 23 86 years), and a
group of 21 patients (mean age 61 years; range 41-82 years) with hypopharynx carci-
noma.
From the same base population, a group of 285 healthy Caucasian blood donors (199
males, 86 females) were recruited at the Blood Transfusion Centre Limburg and
served as a control group, frequency matched on age in 10 year age groups (mean age
50 years; range 19-91). The investigations were approved by the Medical Ethical Re-
view Committee of the University Hospital of Maastricht and informed consent was ob-
tained from all patients and controls according to the Helsinki Declaration II (1975,
revised 1983).
Exposure assessment, blood sampl ing and genotyp ing
Information on tobacco use and alcohol consumption was collected for all patients
and controls by interview. The amount of packyears (PY) was calculated as the number
of years smoking x the number of packs a day (assuming 20 cigarettes = 1 pack). Indi-
viduals were defined as never smokers when they had smoked less than one pack year
cumulatively.
Blood was collected by venapuncture in sterile siliconized EDTA K3 (15%) 4 ml
vacutainer tubes (Becton Dickinson, San Jose. CA, USA). Immediately after collection
whole blood was stored at -20°C until use. Genomic DNA was isolated from whole
blood using the Wizard™ genomic DNA purification kit, according to the instructions of
the manufacturer (Promega, Madison Wisconsin, USA).
Genetic polymorphisms were detected by polymerase chain reaction-restriction frag-
ment length polymorphism (PCR-RFLP). For studying the genetic polymorphism in
GSTP1 a primer set (105F and 105R) was designed so that the presence of the A to G
substitution at codon 313 resulted in the appearance of an Alw261 restriction enzyme
site (9). All primers were synthesized by Life Technologies (Breda, the Netherlands). All
chemicals needed for PCR were purchased from Promega. Madison Wisconsin. USA.
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Statistical analysis
The statistical program SPSS 8.0 for Windows was used. Information on GSFP1 geno-
type, smoking or alcohol was missing in 0, 0, and 11 of the cases and 0, 3, and 1 of
controls, respectively. For the purpose of the analysis, the PY of cigarette smoking
were categorized as <1,1-20, 21-40.41-60. and 60+ PY or in increments of 10 PY. Al-
cohol consumption was categorized as 0-9, 10-50, 51+ gram/day. Because there
were only 3 subjects who indicated never to have consumed alcohol, the first category
consists of 0-9 grams per day. Analyses were conducted for the total group of patients
with HNSCC, as well as for oral cavity/oropharyngeal and laryngeal carcinoma
seperately. Because of small numbers of hypopharyngeal carcinoma, this group was
not evaluated separately.
The association between GSTP1 polymorphisms, smoking, alcohol and HNSCC was
modelled through multivariate logistic regression analysis, controlling for age and gen-
der. First, analyses were conducted to examine the associations between GSfPl ge-
notype and HNSCC, controlling for age, gender, smoking and alcohol. Specifically, we
evaluated whether subjects with GS7P1 M are less susceptible to HNSCC than those
with GSFP1 A8/BB. Likewise associations between smoking and HNSCC or alcohol
consumption and HNSCC were examined, controlling for age, gender and alcohol or
smoking, respectively. The strength of the associations were estimated as Odds Ratios
combined with 95% Confidence Intervals. Subsequently, logistic regression analyses
were performed in which the association between smoking or alcohol and HNSCC (and
its subgroups) was evaluated within subgroups of the GSTP1 genotypes; the wildtype
GSrPl M group and the combined heterozygote/homozygote GSTP1 AB/BB group.
Likelyhood ratio tests were conducted to test statistical significance of regression
model terms, as well as for test for trends and interactions. Two-sided p values are
reported throughout.
Finally, the interaction between smoking and alcohol was evaluated, specifically within
subgroups of the GS7P1 genotypes.
Results
Table 1 shows the frequency analyses for the A to G substitution at codon 313 in the
GS7P1 gene, which was examined in 235 HNSCC patients and 285 controls. The
GS7P1 BB frequency is low in the control group, as well as in the total HNSCC group or
its subgroups. To maintain values for appropriate statistical analysis, we combined the
frequencies for GSTPl AB and GSTP1 BB (Tables 3-5).
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Tatte 1. Frequency distribution of GSfPI genotypes in HNSCC cases and controls
GSrPl genotype Controls All HNSCC cases Oral/oropharynx Larynx
AB
BB
Total
125 (43.9)
121 (42.5)
39(13.6)
285
116 (49.4)
90(38.3)
29(12.3)
235
53(46.5)
48(42.1)
13(11.4)
114
51 (51.0)
36 (36.0)
13(13.0)
100
In Table 2, the frequency distribution is given on the smoking habits and the alcohol
consumption in HNSCC cases, subgroups of HNSCC and the control group. The HNSCC
group in total, as well as the two subgroups, show a significant higher tobacco expo-
sure compared to the control group. The control group shows a significantly lower alco-
hol consumption than the HNSCC cases (total or subgroups). In the oral/
oropharyngeal subgroup, the rate of daily alcohol consumption more than 51
gram/day is much higher compared to the laryngeal subgroup (54.1% vs 30.4% re-
spectively). Alcohol consumption more than 51 gram/day hardly exists in the control
group.
TaM« 2. Frequency attribution of smoking and alcohol consumption In HNSCC cases and controls
CovariaM«
Smoking Packyaart
<1
1-20
2140
4160+
Total
Alcohol Gram/day
0 9
1050
51+
Controls
N(%)
86 (30.2)
130(45.6)
60(21.1)
9(3.2)
285
139 (48.8)
142 (49.8)
3(1.1)
All HNSCC cases
N(%)
13(5.5)
36(15.3)
113(48.1)
73(31.1)
235
18 (8.0)
106(47.4)
100(44.6)
Oral/Or opnarynx
N(%)
7(6.1)
20(17.5)
52 (45.6)
35(30.7)
114
7(6.3)
44 (39.6)
60(54.1)
laryn«
N (%)
3 (3.0)
13(13.0)
53 (53.0)
31(31.0)
100
10(10.9)
54(58.7)
28(30.4)
Total 284 224 111 92
Table 3 shows that the Odds Ratios (OR) for alcohol or smoking are similar in the
HNSCC group as a total and the two subgroups, except for alcohol consumption more
than 51 gram/day, where there is a higher OR in the oral/oropharyngeal group. To pro-
vide appropriate statistical values, smoking is displayed with an increment of 10 PY.
When no adjustment is made for smoking and alcohol (but only for age and gender),
the OR for GSTP1 AA vs GSTPl4ß/Bß will be 1.31 in the total HNSCC group.
The association between alcohol and smoking and the GSTPl polymorphisms is
shown in Table 4. For oral/oropharyngeal cases with the GSfPl AA genotype, alcohol
consumption more than doubles the OR compared to the GSTPl Aß/ßß genotype. This
is also shown for larynx carcinoma. In the oral/oropharyngeal cases, as well as the la-
ryngeal cases with the GS7P1AB/BB genotype. Odds Ratios are increased by smoking
compared with the GSTPi AA genotype. We tested for interaction of alcohol consump-
tion between subgroups of GSTPl in the total HNSCC group; LR (Likelyhood Ratio) -X^
- 0.96, df »2, p>0.05. Also the interaction of smoking between subgroups of GS7P1 in
the total HNSCC group is calculated; LR-X" = 6.04. d f= l . p<0.025.
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Table 3. Association between alcohol, smoking and GSTP1 genotype and HNSCC (total group of cases and subgroup*
of oral/oropharyngeal and laryngeal cancer)
Risk factor Total HNSCC
N-235
Oral/oropharynx
N-114
Larynx
N-100
Alcohol Gram/day
0-9
10-50
51»
Test for trend, p-value
Smoking Packyeara
Increment 10 PY
GSTP1 AB BB
GS7P1AA
OR (95% CD
1.0 * (ref)
5.36 (2.68 - 10.72)
194.16(49.21-766.31)
< 0.001
1.80 t ( 1 5 1 - 2.14)
10 § (ref)
0.99(0.58- 1.71)
OR (95% CD
1.0 • (ref)
8.23 (3.05 - 22.20)
420.03(87.47 - 2016.92)
< 0.001
OR (95% O)
1.0 * (ref)
5.00(1.97- 12.68)
113.36(22.91 - 560.84)
<0.001
1.63 t (134 - 1.97)
1.0 § (ref)
0.78 (0.38 - 1.60)
1.85 t (1 51 - 2.26)
1.0 § (ref)
0.90(0.46- 1.79)
* Odds ratio, adjusted for age. gender, smoking, GSTP1 genotype
t Odds ratio, adjusted for age. gender, alcohol consumption. GSTP1 genotype
§ Odds ratio, adjusted for age. gender, alcohol consumption, smoking
ref • reference value
Cl-confidence interval
Table 4. Association between alcohol consumption, smoking and HNSCC in subgroups of GS7P1 genotype
Risk factor
Subgroup GSTP1 A4
(108 cases. 122 controls)
Alcohol Gram/day
^9
10-50
51+
Test for trend, p-value
Smoking Packyears
Increment 10 PY
Subgroup GSTP1 AB/B8
1116 cases. 159 controls)
Alcohol Gram/day
0-9
10-50
51+
Test for trend, p-value
Smoking Packyears
Increment 10 PY
Total HNSCC
OR (95% Cl)
1.0 * (ref)
7.89(2.75 - 22.68)
232.24 (38.22 - 1407.08)
<0.001
1.51t(1.21- 1.80)
1.0 * (ref)
4.21(1.65- 10.70)
191.67 (20.88 - 1759.33)
«0.001
2.28 t ( 1 7 3 - 3.01)
Oral/oropharynx
OR (95% CD
1.0 * (ref)
15.88 (2.66 - 94.66)
696.88(70.08 - 6930 15)
<0.001
1.34 t (1 10 - 1.80)
1.0 * (ref)
5.57 (1.64 - 18.89)
307.88126.42 - 3588.09)
<0.001
2.41 t (167 - 3.47)
larynx
OR (95% CD
1.0 • (ref)
6.95(1.76- 27.50)
140 16(16 22 - 1211.12)
<0.001
1.63 t (121 • 1.97)
1.0 • (ref)
3.70(107 - 12 84)
74.82(6 76 - 828.31)
<0.001
2.46 t (174 - 3.49)
* adjusted for age. gender, smoking ref - reference value.
t adjusted for age. gender, alcohol Cl • confidence interval
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In Table 5 we show a significant interaction between smoking and alcohol consump-
tion in HNSCC susceptibility when not adjusted for GSTP1 genotype. The effect of
smoking is stronger when more alcohol is consumed (OR increases from 1.27 to 3.53)
However, because of small numbers (especially in high alcohol consumption cate-
gory), interaction between alcohol and smoking and GSTP2 genotype can not be fully
calculated.
TaMa 6. Interaction between alcohol and «moMng regarding nsk of HNSCC. in total group and in subgroups defined by
GSrPl ganotypa
Alcohol calaipry Smoking OR (95% Cl)
per 10 Packyears
rota/ group 0STP1 AA/A«/M
(224 cases, 281 controls)
Alcohol Oram/day
09 1.27(1.03-1.57)
10 50 2.46(1.90-3.20)
51» 3.53(127-9.81)
Tett for interaction smokmg/alcohol. j(2 (p-vahM) 18 2 (p<0.01)
Sutgroup GSTPl A4
(10S cases. 122 controls)
Alcohol Oram/day
&B 1.24(0 96 - 160)
10 50 2.08(144-3.01)
51» j "P
Test for interaction smoking/alcohol, X (p-value)
Subgroup GS fPl AB 88
(116 cases. 159 controls)
Alcohol Gram/day
0-9 143 (0.91 - 2.28)
10-50 2.85(1.96-4.16)
51+ 2 0.57 (0.06 - 5.48)
Test for Interaction smoking/alcohol, X (p-value) 3.5(p>0.05)
n.p. - no estimation possible
Cl - confidence interval
Discussion
Glutathione S-transferases are involved in the detoxification of a wide variety of chemi-
cal carcinogens, including those derived from tobacco smoke (5).
The enzyme GSTP1-1 is known to catalyze the detoxification of PAH in vitro, and may
be a major enzyme involved in the detoxification of tobacco related metabolic products
in vivo (5). The expression in tissues may vary depending on site or localisation, and
immunohistochemical studies have shown a constant and widespread GSTP1-1 ex-
pression throughout pharynx and larynx squamous cell epithelium in both normal and
tumor tissue (10). Earlier we showed that GSTP1-1 is the most important GST enzyme
in human head and neck tissues (30). Therefore, we studied the occurrence of
polymorphisms of this gene (GSIPl) in patients with different head and neck tumors
and controls.
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We previously reported that the GS7M1 and GS7T1 nu// genotypes are not associated
with an increased susceptibility for HNSCC (29). In one of the largest studies per-
formed so far, we found no significant association between risk of HNSCC and occur-
rence of genetic polymorphisms in the GS7P1 gene. This was also found for
oral/oropharyngeal cancers and laryngeal cancers separately.
The GSTP1-1 enzyme is overexpressed in many neoplastic lesions, such as malignan-
cies of stomach, colorectum, bladder, oral tissue, pharynx, larynx, lung, skin and
breast, compared with corresponding normal tissues (5,17-22,30). However, when es-
timating GSTPl-1 serum levels in patients with head and neck cancer, we found signi-
ficantly higher levels compared to controls, but no association with GSTPl genotype
was observed (31). This may indicate that the overexpression of GSTP1-1 in head and
neck cancer is not dependent on genotype but most probably transcriptionally
regulated.
We found a strong association between smoking and alcohol consumption and HNSCC
susceptibility. Assessment of smoking or alcohol consumption is difficult, especially
with respect to patient history for the total accumulative exposure. Exposure usually
takes place over many years and is not always consistent. In addition, different ciga-
rette brands may yield completely different nicotine and tar exposures. High consump-
tion of alcohol often is not revealed by patients because of its social inacceptance. It
therefore would help much to determine additional biomarkers such as serum gamma
glutamyltransferase. which could be indicative of recent consumption of alcohol. De-
velopment of biomarkers which could indicate the exposure and the period of
consumption would be more helpful.
In our control population, GSTPl 86 occurs in 13.6%, and GSTPl AS in 42.5%. Our
data for the healthy controls are in agreement with the genotype frequencies in the
control populations reported by other researchers (9-14). Similar observations were
found for the HNSCC group (12.3% and 38.3% respectively).
Our data for HNSCC patients are also in agreement with several other studies per-
formed. Lin et al. (14) found that polymorphisms in GSTPl were not associated with in-
creased risk for esophageal cancer. They even found a slightly lower occurrence of
GSTPl ^8 or 8S genotypes in cancer and hyperplasia cases than in controls (14).
Jourenkova et al. (32) and Matthias et al. (10) found no association between the
GSTPl 48 or 88 genotypes and risk of larynx cancer. Harries et al. (9) reported an as-
sociation between occurrence of the GSTPl polymorphism and susceptibility to blad-
der or testicular cancer, but found no association with breast or colon cancer. In other
studies no association was found between the GSTPl polymorphism and colorectal,
lung or breast cancer (33,34).
Several other studies, however, revealed a significant correlation between occurrence
of GSTPl polymorphisms and pre-neoplastic and neoplastic lesions. Lung cancer pa-
tients had a significantly higher frequency of GSTPl 88 genotype (15.9%) and a lower
frequency of GSTPl A4 genotype (38.4%) than controls (9.1% and 51.5% respectively)
(12). Homozygous GSTPl 88 was found significantly more often in patients with
Barrett's esophagus and esophageal adenocarcinoma (35). Matthias et al. (10) have
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reported that the GSTP1 polymorphism influences susceptibility to pharyngeal but not
to laryngeal squamous cell carcinoma. However, when comparing our patient groups
in a similar way as Matthias et al. (10) (oral cavity/oropharyngeal SCC and hypo-
pharyngeal SCC versus laryngeal SCC), we did not find a significant difference in the
genotype distributions.
Ryberg et al. (12) reported that patients with the GSTP1 BB genotype had higher DNA
adduct levels in lung tissue than the GS7P1 AA genotypes. They also found a linear
trend between DNA adduct levels and occurrence rates of GSTP1 ß genotypes.
The variant genotypes GSTP1 AB and GSTP1 BB showed a different specific activity
and affinity for several electrophillic substrates but were identical in their affinity for
glutathione (7.15). The properties of the variant genotypes were conducted in "in vitro
experiments" with recombinant proteins by Ali-Osman et al. (7), which however, does
not necessarily provide adequate information on the enzymes and their reactions "in
vivo." In agreement with the in vitro results, Watson et al. (13) and van Lieshout et al.
(35) reported a significantly lower conjugating activity with l-chloro-2,4-dinitroben-
zene (CDNB) in lung and esophageal tissue samples, respectively, in patients with
GSTP1 AB and GSFPl BB compared to GS7P1 AA genotypes.
In summary, we found no evidence for a possible genetic predisposition to HNSCC due
to a genetic polymorphism in the GS7P1 gene. This suggests that the carcinogens in-
volved in the etiology of HNSCC may not be critically dependent on detoxification by the
GSTP1-1 enzyme. Further studies on other combinations of polymorphic genotypes in
detoxification enzymes and their relation to local and systemic enzyme concentration
seem to be justified.
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Abstract
Background Glutathione S-transferase PI (GSTPl-1) is an important enzyme as it
plays a major role in many detoxification reactions, including tobacco related metabo-
lic products. GSTPl-1 is the most abundant of all GST enzymes in normal human head
and neck epithelium, whereas it is overexpressed in head and neck malignancies. At
least three different GSTP1 genotypes exist, AA, Aß and SB, the latter two which have
been correlated with reduced enzyme activity. Many authors have studied the GSTPl
genotypes in relation to the risk for human head and neck squamous cell carcinoma
(HNSCC). A correlation between GSIP1 genotype and GSTPl-1 enzyme plasma levels
has not been made before.
Materials and Method» GS7P1 genotype and GSTPl-1 plasma levels were establis-
hed In 87 HNSCC patients and 51 patients with benign head and neck lesions (BHNL)
who served as controls.
Results For all GSTP1 genotypes (AA, AS and SB) in HNSCC patients the mean corres-
ponding plasma GSTP1 1 values were significantly higher compared to the controls.
There was no significant difference in the plasma GSTPl-1 levels between the diffe-
rent genotypes in HNSCC patients.
Conclusion There Is no association between GSTP1 genotype and GSTPl-1 plasma
levels In patients with head and neck cancer.
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Introduction
Squamous cell carcinoma of the head and neck region (HNSCC) is the 5th most com-
mon malignancy in the world. Most cases of HNSCC are associated with alcohol abuse
or smoking of tobacco but only a small number of individuals do develop HNSCC. This
suggests the influence of genetic components in the susceptibility to HNSCC. Some of
the factors that could explain this difference in susceptibility may be the presence of
polymorphisms in genes coding for enzymes involved in carcinogen metabolism, such
as the glutathione S-transferase (GST) enzymes. GSTs remain a focal point for re-
search because of their role as defense mechanism against xenobiotics such as
polycyclic aromatic hydrocarbons (PAHs), which are an important class of carcinogens
present in tobacco smoke (1). Most precarcinogens have to be activated by phase I en-
zymes such as cytochrome P450 1A1 (CYPlAl) to become a carcinogen in the form of
reactive epoxide intermediates such as benzo[a)pyrene diol epoxide (BPDE) (1). These
carcinogens subsequently may be detoxified by various phase II enzymes such as GST
enzymes.
Human GSTs can be subdivided into five classes, Alpha (A), Mu (M), Pi (P), Theta (T)
and Zeta (Z). Each class includes one or more isoenzymes. Glutathione S-transferase
Pl-1 (GSTP1-1) is a major enzyme in the detoxification of tobacco related metabolic
products (2) and because it is quantitatively the most abundant GST enzyme in the hu-
man head and neck area (3), many researchers have tried to link its genotype to the
risk for HNSCC (4-7).
Several genotypes of the GS7P1 gene have been described, one resulting in isoleuclne
versus valine amino acid substitution at position 104 in the corresponding enzyme (8).
This 104 valine or GS7P1 8 variant is homozygously present in 10% of the Caucasian
population. Approximately 55% of the Caucasian population is homozygous for the
104 isoleucine or GSFP1 A allele, whereas approximately 35% is heterozygous,
containing both alleles (lie and Val).
Homozygosity for the wildtype GS7P1 A allele has been found in a lower incidence in
patients with oral and pharyngeal carcinoma in a Caucasian population (4,5), whereas
a higher incidence of the GS7P1A allele in pharyngeal and laryngeal cancer patients in
a Japanese study has been described (6). Another study revealed no significant differ-
ences in GS7P1 genotypes in laryngeal cancer patients as compared to healthy control
subjects (7). Our group found that genetic polymorphisms of GS7P1 are not associated
with altered susceptibility to HNSCC (9).
GS7P1 genotypes and their possible influence on the risk of other forms of malignant
and benign tumors have been evaluated in patients with lung cancer, where one study
showed a significantly higher incidence of the GS7P1 68 genotype in the cancer group
(1) whereas another study revealed no difference (10). In urogenital malignancies sig-
nificantly higher incidence of the GS7P1 8 genotype was found (11) whereas in gastro-
intestinal malignancies no higher incidence was found (11,12). In the premalignant
Barretts esophagus, however, a higher incidence of the GS7P1 8 genotype was dem-
onstrated (14). In breast carcinoma a higher incidence of the GS7P1 8 genotype was
found as well (15).
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Since the GSTPl-1 enzyme was shown to be overexpressed in a wide variety of tumors
(16), another field of interest is the relevance of plasma GSTPl-1 levels as tu-
mor-marker in several categories of cancer patients (17-21). However, some argu-
ments pleading against a role of GSTPl-1 as a plasma tumor marker in patients with
HNSCC and gastrointestinal cancer were recently given by us (22,23). We found signif-
icantly higher GSTPl-1 plasma levels in HNSCC patients as compared to a group of be-
nign head and neck lesions (BHNL) as controls. However, only 14 % of patients with
HNSCC had plasma levels above the upper normal reference level of 21.8 ug/L, which
was estimated after analyzing samples of 230 healthy blood donors. In the past, sev-
eral investigators have correlated GSFPl genotype and GSTPl-1 tissue levels, e.g. in
lung malignancies (24), in human placenta (25) and in Barretts esophagus (14). They
all found significant differences between the individual genotypes GSTP1 AA Aß and
Bß. An association between the GSTP1 genotype and GSTPl-1 plasma levels in pa-
tients with head and neck malignancies has however never been studied.
Since GSTPl-1 enzyme activity may be associated with GS7P1 genotype (14,24.25),
we now want to investigate whether patients with elevated GSTPl-1 plasma levels all
belong to a certain GSTP1 genotype. Therefore we investigated whether one of the
genotype subcategories differed significantly in mean GSTPl-1 plasma level. We also
compared the mean plasma levels in 51 controls and 87 HNSCC patients in each of
the three genotype subcategories (GS7P1AA, Aß or ßß).
Materials and Methods
A total of 138 patients were included preoperatively during their scheduled admission
at the department of Otorhinolaryngology, Head and Neck Surgery of the University
Hospital of Maastricht between 1995 and 1998. The group consisted of 51 patients
with BHNL who served as controls [23 females (45 %) and 28 males (55 %)] and 87 pa-
tients with HNSCC [21 females (24 %) and 66 males (76 %)], all with no previous
history of cancer.
In the BHNL group the mean age was 49 ± 18 years, range 16-86 years. In the HNSCC
group the mean age was 58 ± 12 years, range 23-82 years. All sites of tumor expres-
sion are given in Table 1.
Table L Site of tumor origin in HNSCC.
Site of tumor origin Number of cases
Oral cavity 25
Oropharynx 23
Hypopharynx 12
Larynx 27
Informed consent was obtained and medical and other anamnestic data were ob-
tained by interview. The Medical Ethical Review Committee approved the investiga-
tions.
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Blood sampling
Approximately 3 ml of blood was collected by venapuncture in vacuumed, silicone-
coated. K3 EDTA-containing tubes (Vacutainer, Order No. 606601, Becton Dickinson,
Grenoble, France). Immediately after collection, blood was gently mixed with the EDTA
solution. Approximately 0.5 ml of whole blood was stored at -20'C for genotyping. The re-
maining was centrifuged for 10 minutes at 3000 X g at room temperature within 2
hours. The upper two-third of the plasma was collected, and care was taken not to aspi-
rate the platelets on top of the cell layer. Plasma samples were stored at -20"C until use.
Assays
GSTPl genotyping
Genomic DNA was isolated from whole blood using the Wizard™ genomic DNA purifica-
tion kit, according to the instructions of the manufacturer (Promega, Madison Wiscon-
sin, USA). Genetic polymorphisms in GSfPl were detected by polymerase chain
reaction-restriction fragment length polymorphism (PCR-RFLP) analysis, using a
primer set (105F and 105R), designed so that the presence of the rare B allele (valine)
resulted in the appearance of an A/w261 restriction enzyme site according to Harries
et al. (11). All primers were synthesized by Pharmacia Biotech (Roosendaal, the Neth-
erlands). All chemicals needed for PCR were purchased from Promega.
Plasma GSTP1-1 measurement
Plasma GSTP1-1 levels were measured using a recently developed enzyme linked
immunosorbent assay (ELISA) (23). Briefly, microtiter plates were coated overnight
with purified anti-GSTPl-1 monoclonal antibody. One hundred uL of standard
(0.4-100 ug/L GSTP1-1), or 1:1 diluted, plasma samples were added to the wells and
incubated overnight. The next day the plateo were washed and incubated with rabbit
anti-GSTPl-1 serum, washed again, and incubated with horseradish peroxidase-la-
beled swine anti-rabbit antibody; and after a final wash, plates were stained with
O-phenylenediamine- H ^ . Standards and samples were measured in duplicate. A
four-parameter weighted logistic regression model was used to calculate standard
curves and unknowns. The assay had no cross-reactivity with GSTs of the Alpha or Mu
classes; the detection limit was 0.4 ug GSTP1-1 /L, and the intra- and inter-assay coef-
ficients of variation were 5.8% and 10.9%, respectively.
Stat is t ica l analysis
For statistical analysis we used the statistical package SPSS for Windows 8.0. The sta-
tistical significance of differences between the individual means for the control and
HNSCC groups for each genotype was tested with an independent t-test for equality of
means. Possible unreliable variables were detected by the Cooks test.
The significance of the difference of means for the different genotypes in each cate-
gory of disease (benign, malignant or total) was tested with a One-way Analysis of Vari-
ances, combined with a Levene's test for equality of variances and completed with
Bonferroni and Tamhane post-hoc tests.
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Results
The results of the assays and different comparative tests are shown in Tables 2-4.
The distribution of genotypes in the whole study group (HNSCC and BHNL controls)
was 62 individuals (44.9%) with the GS7P1 A4 genotype, 56 (40.6%) with the AB geno-
type and 20 (14.5%) with the 68 genotype. For the control group this was 26 individu-
als (51.0%) with GS7P1 A4, 18 (35.3%) with -48 and 7 (13.7%) with the 88 genotype.
For the HNSCC group the distribution was 36 individuals (41.4%) with GSIP1 A4, 38
(43.7%) with Aß and 13 (14.9%) with the 88 genotype.
Table 2 shows the mean GSTP1-1 plasma levels according to GS7P1 genotype in the
two study groups (HNSCC and controls). For all GSTP1 genotypes (A4, A8 and 88) in
HNSCC the mean and median values were higher as compared to corresponding con-
trols. The highest mean values were observed in the heterozygotic GSTP1 AS groups in
both study groups.
Tabta 2. Plaima GSTP1 1 levelt.
Group
Control
HNSCC
Total
Gsrpi
Genotype
AX
AB
BB
Total
AA
AB
BB
Total
AA
AB
BB
Mean*
91
9.9
9.3
9.4
12.0
19.8
15.0
15.9
10.8
16.6
13.0
N
2«
18
7
51
36
38
13
87
62
56
20
Sd*
3.2
6 1
4 5
4.5
5.1
26.1
5.3
17.9
4.6
22.1
5.6
Minimum*
5.1
42
3 3
3.3
4.6
3.7
9.3
3.7
4.6
3.7
3.3
Maximum*
17.9
3 2 3
1 5 9
32.3
26.8
141.5
2 6 8
141.5
26.8
141.5
26.8
Median*
8 3
82
7 4
8.2
10.7
11.8
14.5
11.2
9.5
10.0
12.8
Total 13.5 138 14.8 3.3 141.5 10.0
* Values are given as ug/L.
N: number of subjects in each category.
Sd: standard deviation.
Table 3 shows the results of the independent samples t-tests in order to compare the
mean GSTP1-1 plasma values in each genotype subgroup. When comparing the
HNSCC to the control group for the GSTP1AA genotype, plasma GSTP1-1 values were
significantly higher in the HNSCC-group (12.0 and 9.1 ug/L respectively, p = 0.008). A
similar result was obtained for the AB genotype, even when corrected for one abnor-
mal high value (141.5 ug/L) which appeared unreliable according to Cook's test (19.8
vs. 9.9 ug/L, p - 0.031). The GS7P1 8B genotype also showed a difference that was
significant (15.0 vs. 9.3 ug/L, p = 0.028). The difference in GSTP1-1 plasma values for
the combined control and HNSCC groups was significant as well (9.4 vs. 15.9 ug/L,
p-0.002).
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Table 3. Companson of mean GSTP11 enzyme plasma levels m the GSfPl genotype subgroups (Ttests.)
GSfPl genotype '"'"*' Control vs. HNSCC (p-values)
AA
AS
AB. exclusion of highest value
86
0 0 0 8
0.031
0.035
0.028
Total 0.002
(Difference in GSTP 1 1 plasma level between control and HNSCC for the different genotypes)
Table 4 shows the results of one-way analyses of variance to compare the mean
GSTPl-1 plasma concentrations for the different genotypes in each study group. The
difference between the mean plasma GSTPl-1 levels for each GS7P1 genotype in the
control group was not significant (9.1 (AA); 9.9 (AS) and 9.3 ug/L (BB) respectively,
p=0.862). Neither was it for the HNSCC group (12.0; 19.9 and 15.0 pg/L. p-0.170)
and the total of both groups (both controls and HNSCC) (10.8; 16.6 and 13.0 ug/L,
p=0.100).
Table 4. Comparison of mean GSTPl-1 enzyme plasma levels for the different GSTP1 genotypes In the control and
HNSCC population (One-way analysis of variances.)
G,oup ANOVA significance (p-values)
Control 0 8 6 2
HNSCC 0.170
Total 0.100
I Differences In mean GSTP 1 1 plasma level between the genotypes in control. HNSCC and both)
Discussion
The purpose of this study was to evaluate the possible association between the ge-
netic polymorphisms in the GS7P1 gene and the phenotypic expression (GSTPl-1
plasma levels) in patients with malignant head and neck tumors.
No previous studies have been performed on the correlation between GS 7P1 genotype
and GSTPl-1 plasma level. However, a correlation between enzyme function and
GSTP1 genotype has been made before (8,14,24,25). Ali-Osman et al. and Zimniak et
al. have provided evidence of polymorphisms in the human GS7P1 gene locus, result-
ing in functionally different GSTPl-1 proteins (8,25). Watson et al. and van Lieshout et
al. found significant differences in GST enzyme conjugating activity between the
GSTP1 M wildtype and the AB and BB genotypes in lung and esophageal tissues, re-
spectively (14,24).
We found no significant correlation between the different GSTP1 genotypes and the
corresponding GSTPl-1 plasma levels. This was the case when the control- and
HNSCC-groups were investigated separately and also when they were combined. This
means that both in patients with HNSCC and controls, no direct relation was present
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between GS7P1 genotype and GSTP1-1 phenotype, as was found earlier in lung or
esoephageal tissue of patients with corresponding lung or esophageal lesions (14,24).
In a previous study on HNSCC we found that GSTP1-1 is not a plasma tumor marker for
individual patients, despite the fact that median plasma levels in HNSCC were signifi-
cantly higher as compared to controls, but only a small part of HNSCC patients had
plasma levels elevated above the normal reference level of 21.8 ug/L (22).
When comparing HNSCC to controls, significantly different GSTP1-1 plasma levels
were found for all GSTP1 genotype categories. These findings show that there is no dif-
ference in the influence of the genotypes on GSTP1-1 plasma levels between HNSCC
and controls. The control group had a slightly higher percentage of GSFP1 AA geno-
types than the HNSCC group (51.0% vs. 41.4%) and a lower percentage of GSfPl AS
genotypes (35.3% vs. 43.7%). The clinical significance of this difference has to be in-
vestigated In a larger patient group.
Hirata et al. considered estimation of GSTP1-1 plasma levels a useful aid for early diag-
nosis, prediction of tumor extent and determining treatment efficacy and prognosis for
oral cancer (17). We did not find arguments for such a role of GSTP1-1 for our HNSCC
patients (22). The question is whether this difference can be explained by either meth-
odological, racial or demographic factors or by the fact that Hirata et al. limited their in-
vestigation to oral cancers (17). Another explanation could be that the Japanese and
Dutch patient groups investigated have a different distribution of GS7P1 genotypes.
The GSTP1 frequency distribution in the Dutch population is 55% for GS7P1M, 35%
for GS7P1 AS and 10% for the GSTP1 B8 genotype. Hirata et al. (17) give no data on
the genotype distribution, but another Japanese study by Morita et al. (6) indicates a
frequency distribution of 69% for GSTP1 A/A, 29% for the AS and 2% for the SB geno-
type, which indeed differs considerably as compared to corresponding data in our
Dutch population.
We conclude that there is no clear association between GS7P1 genotype and GSTP1-1
phenotypic expression in the form of plasma levels in patients with head and neck le-
sions as was found previously for GST enzyme activity in tissues of patients with lung
cancer (24) or Barrett's esophagus (14). Perhaps further investigation of the corre-
sponding GSTP1-1 tissue enzyme activity in head and neck patients will reveal such a
correlation.
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Abstract
Background Genetic polymorphisms in single biotransformation enzymes may modu-
late the risk for head and neck squamous cell carcinoma (HNSCC). A pilot study evalu-
ating the effect of combined polymorphisms in the glutathione S-transferase (GST) or
the epoxide hydrolase (EPHX) genes was performed in order to determine whether
such a combination of polymorphisms influences the risk for HNSCC.
Materials and Methods Genotyping by PCR or PCR-RFLP of the GSTM1 and GS7T1
nuW polymorphisms, the GSTP1 8 variant and the Tyr 113 His variant of exon-3 of EPHX
was successfully performed from 225 patients with HNSCC and 266 healthy controls,
recruited at the University Hospital Maastricht.
Results An analysis on the simultaneous occurrence of multiple polymorphisms in
any of the genes described above, without adjusting for age, gender, smoking or alco-
hol consumption, revealed no statistical differences between patients with HNSCC
and healthy controls.
Conclusion A combination of multiple polymorphisms in the GST and EPHX genes is
not associated with a higher susceptibility for HNSCC.
84
Introduction
The risk of head and neck squamous cell carcinoma (HNSCC) is strongly associated
with smoking of tobacco and consumption of alcohol (1), which may be responsible for
a considerable load of (pre)carcinogens. Metabolism and detoxification of such exoge-
nous harmful compounds often occurs by phase I and phase II enzymes such as
epoxide hydrolase (EPHX) and glutathione S-transferase (GST).
Because genetic polymorphisms exist in glutathione S-transferase GSTM1, GSTT1,
GS7P1 and EPHX, which may lead to complete absence of (GSTM1 and GS7T1) or par-
tially deficient (GSTP1 and EPHX) corresponding enzyme activity, individuals bearing
such genetic polymorphisms and therefore lack of a (partially) functional enzyme, may
be at a higher risk of developing tobacco and alcohol related cancers (2-4). We have
earlier investigated involvement of single polymorphisms in biotransformation en-
zymes in modulation of HNSCC risk (2-4) and found that the GS7T1 nu// genotype may
modulate the risk of head and neck cancer (HNSCC) (Chapter 3). Reports in the litera-
ture are very conflicting on the significance of GST polymorphisms in HNSCC suscepti-
bility (5-12). Possibly, this is due to: 1. the relatively small patient and control study
groups in most papers, 2. insufficient matching of patients and controls, and 3. the
use of different methods for genotyping between the various research groups and
sometimes even within the same study.
Since chemical modification of compounds to be detoxified is very complex and often
requires several subsequent chemical reactions catalyzed by several different en-
zymes, we evaluated whether the simultaneous lack or dysfunction of one or more GST
and EPHX enzymes as a result of a polymorphism in the corresponding gene, may influ-
ence the susceptibility for HNSCC.
Materials and Methods
Data and results of GST and EPHX genotyping obtained by polymerase chain reaction
method (PCR) in material collected from HNSCC patients and healthy blood donors
from earlier studies was used (2-4,13). The PCR methods for genotyping of GSTM1,
GSTT1, GSTP1 are described in detail in our earlier studies (Chapters 2, 3 and 5)
(2-4,13). The PCR method for EPHX is described in detail by Zusterzeel et al. (14) and
will be briefly described below. The polymorphism Tyr 113 His in exon 3 was examined.
DNA samples were amplified by PCR. The PCR mixture contained approximately 100 ng
of genomic DNA, 50 mM KCI, 10 mM Tris HCI pH 8.0, 2 mM MgCI,, 1.5 u Taq polymer-
ase. and 1 uM of amplification primers in a total volume of 50 pL Denaturing of DNA dur-
ing 5 min at 94°C. Thirty amplification cycles. PCR product digestion with T h t l l l and run
on 3% agarose gel. Identification of 113 His by 2 DNA bands (209 and 22 base pairs),
and detection of 113 Tyr by an undigested DNA band of 231 base pairs.
Chi square and Odds Ratio (OR) analysis was made to compare polymorphisms of one
or more of these genes in 225 patients with head and neck squamous cell carcinoma
(HNSCC) and 266 healthy controls. Statistical analysis was performed by using SPSS
8.0 software.
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Results
In patients as well as in controls, an analysis on the number of genetic polymorphisms
(0-4) in GST or EPHX. co-occurring in the same individual was performed. The results
are shown in Table 1. As the Odds Ratios clearly show, no significant difference is
found between the group of HNSCC patients and the healthy controls with respect to
the co-occurrence of 0-4 different genetic polymorphisms in the detoxification
enzymes studied here.
TaM« 1 Number of ftnetic porymorphwms in GSfMl. GSTTl. GSfPl or EPHX in patients with HNSCC and healthy
control»
Polymorphism» HNSCC
N-225(%)
Controls
N-266(%)
Odds Ratio
OR (Cl 95%)
11(9)
52 (23)
71(32)
70(31)
21(9)
15(6)
64(24)
90(34)
77(29)
20(7)
1.1 (0.5-2.6)
1.1(0.5-2.5)
12(0 5-2 9)
1.4 (0.5-3.9)
Discussion
Tobacco smoke may contain a considerable number of carcinogens, and the metabo-
lism of each carcinogen may be very complex, involving the interaction of several
blotransformation enzymes, such as cytochrome P450, epoxide hydrolase, gluta-
thione S-transferases and many others. In the studies we have performed so far, we
have not found evidence that single genetic polymorphisms in CVP or GSfs are major
modulators for the risk for head and neck cancer. Individually however, these meta-
bolic polymorphisms may be very weak risk factors, explaining also the variable result
in the literature. But in combination with other polymorphisms, which each confer a
very small risk, the sum up of those small risk factors may become large enough to be
visible. However, we found no evidence in our study for such a sum up effect of the four
polymorphisms investigated here.
We conclude that co-occurrence of up to four different polymorphisms in the GSfand
EPHX genes are not associated with a higher susceptibility for HNSCC. The results of
this pilot study remain in agreement with the results presented in the other chapters,
since no effect at all or only a slightly protective effect of the GS7T1 nu// genotype was
found. DNA mapping and evolving techniques may create new possibilities for the si-
multaneous investigation of many polymorphisms in biotransformation enzymes in the
near future.
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Abstract
Background Variants in genes coding for phase I and II enzymes such as the cy-
tochrome P450 (CYP) family and glutathione S-transferases (GST) may alter individual
susceptibility to cancer. GS77W1, GS7T1, GS7P1 and CYP1A1 polymorphisms may be
associated with head and neck cancers though evidence from previous studies has
not been consistent.
Materials and Motho'k We conducted a meta-analysis of 30 published case-control
studies on these polymorphisms including 4,286 head and neck cancer cases and
5,440 controls. Subsequently, in a pooled analysis of original data from 9 published
and 2 unpublished case control studies (2,324 cases and 2.766 controls), we explo-
red the same associations as well as potential gene-gene and gene-environment inter-
actions.
Results The summary Odds Ratios from the meta-analysis were 1.24 (95%CI»1.11,
1.38) for the GSTM1 nu// genotype, 1.20 (95%CI-1.00,1.44) for the GS7T1 nu// geno-
type. 1.10 (95%CI-0.92, 1.31) for the va//ne genotype of the GSTP1 polymorphism at
codon 104 and 1.27 (95%CI-0.99. 1.63) for the va//ne genotype of the CYPLA1 poly-
morphism at exon 7. Sources of heterogeneity included sample size, geographic
region, year of publication and matching status. The results of the pooled analysis also
supported an association of the GSTM1 nu// genotype (0R=1.32, 95%CI = 1.07, 1.62)
and GS7T1 nu//genotype (0R=1.35, 95%CI=1.13, 1.61) with head and neck cancers.
An association was suggested for multiple GST genotypes and head and neck cancer
risk.
Conclusion Our meta analysis results support the concept of a moderate association
of GSTM1, GS7T1, CYP1A1 polymorphisms and the risk of head and neck cancers.
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Introduction
The study of low penetrance genes in head and neck cancers is of importance since
even low risk genes can be a substantial public health burden when the polymorphism
is common (1). Variants in genes coding for phase I and phase II enzymes such as the
cytochrome P450 (CYP) and glutathione S-transferases (GST) families may potentially
alter individual susceptibility to cancer. Several studies have been conducted on po-
tential genetic risk factors for head and neck cancer and a recent review on GSTM1
and GSTT1 polymorphisms summarized the results of case-control studies as incon-
clusive (2). Of the 21 studies reviewed for the GSFM1 nu// genotype. 13 studies re-
ported ORs between 0.9 and 1.3, while 8 studies reported ORs between 1.4 and 3.9
(2). For the GSTT1 nuH genotype. 8 studies reported ORs from 0.5 to 1.2, while 6 re-
ported ORs from 1.4 to 2.6 (2). Since these metabolic enzymes may be among nume-
rous genes involved in the multistage pathway of cancer, they are expected to be low to
moderate risk factors that may be difficult to detect. However, even a moderate effect
on cancer risk would be of biological and medical importance because of the possibi-
lity of identifying high risk individuals for target prevention activities.
Tobacco smoke contains a range of different carcinogens including polycyclic aro-
matic hydrocarbons (PAH), aromatic amines and nitrosamines (3). The amount of car-
cinogenic exposure to the upper aerodigestive tract will depend on whether the
carcinogen is activated by phase I enzymes and whether it is detoxified by phase II en-
zymes. Variants in genes coding for these enzymes may therefore alter the individual's
exposure to tobacco carcinogens. The CYP1/U gene codes for a phase I enzyme that
activates tobacco procarcinogens such as benzo[a]pyrene and aromatic amines, into
their carcinogenic forms (4). A point mutation in CVP1/U exon 7, resulting in an amlno
acid replacement of isoleucine by valine in codon 462, which is strongly linked to
3801T>C in the 3'-flanking region, was reported to be associated with increased en-
zyme activity (5,6). The variant genotype is suggested to be harmful possibly by In-
creasing carcinogen activation and generating reactive oxygen species (7). Moreover,
smokers with the CVP141 variant polymorphism were shown to have elevated DNA
adduct levels (8).
The GST family includes phase II enzymes that detoxify carcinogens and reactive oxygen
species (9). Individuals who have homozygous deletions for the GSTM1 and 71 gene
have no GSTM1-1 and Tl-1 enzyme activity. Lack of these enzymes may potentially in-
crease cancer susceptibility because of a decreased ability to detoxify carcinogens such
as benzo[a]pyrene-7,8-diol epoxide, the activated form of benzo(a)pyrene. The GSTPl
polymorphism at codon 104 results in the replacement of isoleucine by valine due to an
A —> G transition. The valine variant of the GS7P1 polymorphism may be 2-3 times less
stable (10) and may be associated with a higher level of DNA adducts (11).
The previous review on GSTMl, GS7T1 and head and neck cancer included papers
written in English and published between 1993 - 2000 (2). Since papers on 12 addi-
tional study populations not included in the review are available (12-23), we con-
ducted an updated meta-analysis of head and neck cancer case-control studies on
GSTM1, GS7T1. and additionally on GSTPl. CYPL41 to assess whether the available
evidence supports an association and to determine the sources of heterogeneity
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among the study results. In addition, we pooled the raw dataset from 11 case-control
studies on these metabolic genes and head and neck cancer, to explore the main ef-
fect of the genes, as well as gene-gene and gene-environment interactions.
Materials and Methods
Meta-Analysis
A MedLine search was conducted for case-control studies reported up to March 2003
of GST/vJl, GS7T1, GSTP1 and CYP1A1 on the risk of head and neck cancer, including
oral, pharyngeal and laryngeal cancers. We focused on the nu// polymorphism of the
GSTMl and GS771 genes, the //elO4Va/ polymorphism of the GSTP1 gene, and the
//e462Va/ polymorphism of the CVP1A1 gene. The following keywords for genotypes
were used in the MedLine search: "Glutathione," "GSTM1," "GSTT1," •GSTP1" and
"CYP1A1." In addition, we reviewed the literature cited by each of the papers that we
identified. A total of 36 publications were identified including 30 different populations
(12-48).
We focused on studies that genotyped individuals for the polymorphisms by PCR (poly-
merase chain reaction) and excluded 23 studies that assessed gene expression via
measurement of protein levels. Positive controls for the GSTM1 and GS7T1 genotyping
were mentioned for the majority of studies. GSTP1 was genotyped in all studies by
RFLP (Restriction Fragment Length Polymorphism)-PCR. For CVP1/U genotyping, 3
studies used allele specific PCR (14,33,46), 1 study used PCR-SSCP (single-strand
conformational polymorphism)(43) and the other studies used RFLP-PCR. When se-
veral papers were identified for the same population, we referred to the most updated
information source. Studies that did not report Odds Ratios (ORs) and 95% confidence
intervals (CIs) and did not provide enough data to estimate crude ORs were excluded
(49-51).
For each study we abstracted the date of publication, the country where the study was
conducted, the organs within the head and neck cancer studied, the control source
(hospital, hospital-healthy, population-based or mixed), the number of cases and con-
trols, and whether controls were matched to cases (matching, frequency matching, no
matching). Healthy subjects recruited from hospitals as controls were categorized as
'hospital-healthy.'
S ta t is t ica l Analysis
We abstracted crude Odds Ratios (ORs) from the studies when available. We calcu-
lated for each study, crude ORs and 95% CIs when the study: 1) did not estimate the
OR but presented enough data for estimation, 2) reported an OR adjusted for various
factors. 3) reported only ORs stratified by factors such as race or site. For a study from
France, we combined the data for cancers of the oral cavity, pharynx and larynx that
had been presented in separate publications (30-32).
When both the data and crude ORs were presented, we checked the calculation for the
crude ORs and 95%Cls. In the case of discrepancy (22), we retained the crude OR that
we calculated, since the OR presented in the original publication may have been ad-
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justed for some factors. We did not perform a meta-analysis of the adjusted ORs be-
cause adjustment was not comparable among the studies. For the GSTP1 and the
CVP1A1 polymorphisms, we combined the heterozygous and homozygous poly-
morphisms due to the limited number of subjects who were homozygous mutant.
Whenever possible we estimated or extracted study-specific ORs separately by organ
within the head and neck (oral cavity, pharynx, larynx), and by smoking status (never,
ever smokers). For 4 studies, we were unable to separate cancer cases of the
nasopharynx, nasal cavity, sinus or salivary gland from other head and neck cancers
(28,36,39,42). The histology of head and neck cancer cases was squamous cell carci-
noma (SCO in most studies, but 2 studies (22,29) did not specify the histology and one
study (36) included 20 out of 156 cases with "other miscellaneous histologies."
Summary ORs were estimated with the statistical program STATA by inverse-variance
weighting, using a random effects model that includes a term for heterogeneity be-
tween studies (52). Tests for heterogeneity between the studies were conducted for
each analysis. Publication bias was assessed with Begg's funnel plots (53) and Egger's
regression asymmetry test (54).
We conducted an influence analysis, where each study was excluded one at a time to
determine the magnitude of influence on the summary estimate. We excluded several
studies that appeared to be less consistent with the other studies in order to ensure
that a few studies were not responsible for excessively influencing the summary esti-
mate. We also excluded some studies that resulted in asymmetry in Begg's funnel plot,
in an attempt to minimize publication bias. Both summary estimates including all stud-
ies identified and excluding several studies were presented.
Summary ORs were presented by specific organs within the head and neck and by
smoking status. The meta-analysis was also stratified by geographic region (Asia,
North America, Europe), period of publication (1995-1999, 2000-2002), number of
subjects (<100 cases or <100 controls, >100 cases & >100 controls), matching of
cases and controls (matched, frequency matched, not matched), and control source
(hospital, hospital-healthy or population based). Summary ORs were estimated when
there were at least 3 risk estimates available.
Pooled Analysis
The data on GSTM1, GS7T1, GSTP1, CVP1/U and head and neck cancers for the
pooled analysis was extracted from the International Collaborative Study on Genetic
Susceptibility to Environmental Carcinogens (GSEC) database (55,56), which contains
individual level data from case-control studies on genes that metabolize environmen-
tal carcinogens. Investigators who had published their results from case-control stud-
ies on genetic polymorphisms and cancers were identified through a MedLine search
and requested to provide published and unpublished original data from their studies.
Our data included 11 case-control studies, of which 9 had been published and in-
cluded in the meta-analysis (12.25,26,28,30-32.34,35,37,38,42-45). Cases of can-
cer of the nasopharynx, maxillary sinus and salivary glands were excluded from the
analysis. Of the 2,324 head and neck cancer cases included in the analysis, there
were 840 oral cavity cancers, 501 pharyngeal cancers, 904 laryngeal cancers and 79
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cases with cancer at an unspecified organ within the head and neck. The control group
included 2,766 subjects.
Statistical Analysis
In order to assess the association of the polymorphisms with head and neck cancer,
the logistic regression model was used to estimate study-specific ORs and their 95%
CIs. We estimated a crude OR and an OR adjusted for age, sex and race for each study.
In the case of GSrPl and CVP1A1, we combined heterozygous and homozygous mu-
tant genotypes for consistency with the meta-analysis approach. ORs estimated for in-
dividual studies and numbers of cases and controls may not precisely match those
reported in the publications. Heterogeneity between studies was assessed with the
test for heterogeneity while publication bias was assessed with the Begg's funnel plots
(53) and Egger's regression asymmetry test (54). A summary OR was estimated by in-
verse-variance weighting, with the random effects model because of the heterogeneity
detected among studies (52). Studies identified from the influence analysis and
Begg's funnel plots were excluded in an attempt to minimize bias. Stratified analysis
was conducted by cancer site and smoking status, as well as for Caucasians and cases
with squamous cell carcinoma only. In the pooled analysis, we did not assess the
effect of study characteristics due to the small number of studies available.
RAftllltft
Study-specific crude ORs and overall summary ORs from the meta-analysis of GS7M1,
GS7T1, GSTP1, CVP1A1 polymorphisms are shown in table 1. The distribution of the 4
polymorphisms among the head and neck cancer cases and controls from the 30 po-
pulations are presented in table 2. The frequency of the genotypes varied between
geographic regions among controls: 24.7 - 57.8% for the GS77W1 nu//, 8.3 - 52.8% for
GS7T1 nu//, 23.8 - 64.6% for the GS7P1 va//ne genotype and 5.8 - 39.5% for the
CVP1A1 va/me genotype. The percentage of Caucasians in the U.S. studies were:
88.9% in cases and 87.9% in controls (24), 95.6% in cases and 93.3% in controls (39),
62% in cases and 86% in controls (41), 100% in cases and controls (43), 66.2% in
cases and 67.3% in controls (44), 61.5% in cases and controls (45), or not specified
(15,48).
In the meta-analysis of the GS7M1 polymorphism, 29 studies were identified with a to-
tal of 4,096 cases and 5,146 controls (Table 1. Figure 1). The overall summary OR was
1.36 (95%CI-1.17, 1.58) when adjusted for study center (Table 3). Two studies were
excluded as they were less consistent with the other studies (12.17) and 4 studies
were excluded to minimize the publication bias suggested by the funnel plot shown in
Figure 2(15,18,20,25). These 4 studies were of a small sample size and had all identi-
fied a strong positive association. In the final model including 23 studies (3,407 cases
& 4,373 controls), the OR for the GSFM1 nu// genotype was 1.24 (95%CI=1.11. 1.38)
and it was particularly high for oral cavity cancer and among ever smokers. The ORs for
the GSTMl nu// genotype was higher for studies with smaller sample sizes than for
larger studies (p-0.072). Differences between ORs in other strata were not identified.
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The summary OR for the 19 studies identified for the meta-analysis of GS7T1 and head
and neck cancers was 1.18<95%CI-0.97, 1.44) (Table 3). Three studies (15,18,24)
were excluded since they appeared to be divergent from the other studies and another
(18) was excluded to minimize the potential publication bias that was identified in
Begg's funnel plot (Figure 3). Including 2,679 cases and 3,104 controls from 15 stud-
ies, the summary OR for the GS7T1 nu// genotype on the risk of head and neck cancers
was 1.20 (95%CI»1.00,1.44). The small number of available studies limited the ana-
lysis stratified by cancer site. The summary ORs were higher for studies from Asia
(p-0.061), studies published from 2000 to 2002 (p=0.031) and matched stud-
ies (p-0.011).
A small number of publications was identified on GSIP1 and CVP1A1 polymorphisms
and the risk of head and neck cancers. For GS7P1, we identified 9 case-control studies
with 1,768 head and neck cancer cases and 1,699 controls (Table 4). None of the
studies was excluded since there were no strong indications of excessive influence or
publication bias. There was some suggestion that the valine genotype of GSTPi may
elevate the risk of head and neck cancer (summary 0R=1.10.95%CI=0.92,1.31), and
specifically the risk of oral cancer. Summary ORs for some strata could not be esti-
mated due to the small number of studies.
Eleven case-control studies were identified for the association between the CVP:M.l
polymorphism and head and neck cancers, with a summary OR of 1.50 (95%CI=1.00,
2.26). Three studies (22,33,39) were excluded as they appeared to be less consistent
with the other studies. According to the meta-analysis of the remaining 8 studies with
1.340 cases and 1,265 controls, the risk of head and neck cancers may be increased
moderately by the CYP1/U va/ine polymorphism (OR-1.27, 95%CI=0.99, 1.63).
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Figure 3. Begg's funnel plot of 19 studies in the meta-analysis of the GS7T1 nuH genotype and head
and neck cancer (darkened circle - study excluded from final model)
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Results of the pooled analysis of GS7M1. GSTTl. GS7P1. CVP1/U and head and neck
cancers are shown in Table 5. The race/ethnicity distribution for the Lazarus study was
64.3% Caucasian and 35.7% African-American among cases, and 61.8% Caucasian
and 38.2% African-American among controls. For the Romkes study, the cases were
97.4% Caucasian and 2.6% African-American, while the controls were 78.9% Cauca-
sian, 15.5% African-American, 4.2% Latino and 1.4% Asian. All 11 studies in the
pooled analysis had data on GSTM1. but two studies were excluded since their study
estimates were less consistent with respect to the other studies (12,26). When includ-
ing all studies, the OR was 1.32 (95%CI=1.07, 1.62) adjusting for study center. After
excluding the 2 studies, the OR for the GS7M1 nu// genotype, adjusted for study center
was 1.35 (95%CI=1.13,1.61) and the OR adjusted for study center, age, sex and race
was 1.32 (95%CI=1.04, 1.69). The GST7H1 nu// genotype was associated with an in-
creased risk of head and neck cancers among smokers and Caucasians. The risk of
head and neck cancer was also elevated by the GSTTl nuH genotype (OR adjusted for
study center=1.35, 95%CI=1.13, 1.61; OR adjusted for study center, age, sex and
race=1.41,95%CI=1.00,1.57), but not by the GS7P1 and CVP1A1 polymorphisms, ac-
cording to the pooled analysis. There appeared to be heterogeneity among the studies,
especially in the case of the GSTP1 polymorphism.
Gene-gene interactions were assessed for all combinations of GST7W1, GSTTl, GSfPl
and CVP:M1 on the risk of head and neck cancers in the pooled analysis, but strong in-
teractions were not identified. We also analyzed the data for possible gene-environ-
ment interactions between each polymorphism and smoking, but again interactions
were not obvious. However, we did see an increasing risk of head and neck cancers
with multiple GST polymorphisms in an analysis of a subset of studies that had data on
all 3 polymorphisms (906 head and neck cancer cases and 543 controls) (26,30-
32,37,38,42). The nu// genotypes GST7W1 and GSTTl, and the va//ne polymorphism of
GSIP1 were considered high risk relative to subjects who had low risk genotypes for all
3 GSTs. Taking subjects with all low risk GST polymorphisms as the reference, the OR
was 1.13 (95%CI=0.83, 1.53) for subjects who had 1 high risk GST polymorphism,
1.19 (95%CI=0.87, 1.63) for subjects who had 2 high risk GST polymorphisms and
1.69 (95%CI=0.99, 2.88) for subjects with all 3 high risk GST polymorphisms when ad-
justed for study center (test for trend, p-value=0.08). When further adjusted for age,
sex, and race, the OR was 1.16 (95%CI=0.83. 1.63) for 1 high risk GST polymorphism,
1.23 (95%CI=0.86, 1.75) for 2 high risk GST polymorphisms, and 2.06 (95%CI-1.11,
3.81) for having 3 high risk GST polymorphisms (test for trend, p-value-0.04). When
stratified by smoking, the results were not statistically significant.
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Year of Publication
1995 1999
2000-2002
Number of cases & controls
< 100 cases or < 100 controls
?100 cases & jcontrols
Control Source
Hospital Healthy or Population
Hospital
Matching
Matched
Frequency matched
Not matched
No. of
studies
29
23»
9^
3"
7*
38
6 '
8
6
9
13
10
10
13
13
10
5
4
14
OR* for nu«
genotype (95%CI)
1.36(1.17.1.58)
1.24(1.11. 1.38)
1.31(1.02.2.69)
1.14(0.77.1.67)
1.17 (0.90. 1.54)
1.00(0.57.1.75)
1.27 (0.98. 1.64)
1.42(1.19.1.79)
1.24 (0.98. 1.57)
1.13 (0.99. 1.30)
1.27 (1.09. 1.47)
1.20(1.02.1.40)
1.45(1.19.1.77)
1.17 (1.03.1.32)
1.32 (1.11.1.57)
1.17 (1.02. 1.34)
1.32(1.04.1.67)
1.12(0.91.1.37)
1.28(1.09.1.49)
Test for
Heterogeneity
0.00
0.22
0.13
0.58
0.10
0.69
0.07
0.14
0.17
0.76
0.17
054
0.49
0.26
0.08
0.66
0.47
0.70
008
Egger,
Test
0.20
0.11
0.79
0.17
0.10
0.66
0.49
0.62
0.76
0.27
0.44
0.12
0.54
0.99
0.08
0.96
0.70
0.78
0.07
No. Of
studies
19
15=*
6«
~4lO
5
4
6
8
7
7
8
8
7
3
3
9
OR* for nu/(
genotype (95%CI)
1.18(0.97.1.44)
1.20(1.00.1.44)
1.28 (0.93.1.76)
1.13(0.70.1.81)
1.31 (0.90.1.89)
1.48(1.03.2 13)
1.43 (0.97. 2.09)
0.98 (0.81.1.20)
1.01 (0.83.1.23)
1.49(1.11.2.00)
1.45(0 98.2.14)
1.11(0.93.1.33)
1.13(0.90.1.40)
1.32 (0.96.1.81)
1.82 (1.29. 2 57)
1.38 (0.99.1.93)
1.01 (0.83. L24)
Test for
Heterogeneity
0.00
0.11
0.23
0.09
0.17
0.15
0.28
0.64
0.65
0.12
0.09
0.35
0.24
0.10
0.50
0.95
0.31
Egger't
Test
0.98
0.31
0.73
0.81
0.86
0.58
0.47
0.33
0.93
0.18
0.54
0.68
0.44
0.70
0.18
0.52
0.77
^^Ä^^
14. MdMnalyaü of awe-control studies for GSTP1 flLEVAU CVP1A1 (X£VAU and head and neckc^
GSTP1
t-»
O
Overall
Excluding several studies
CancarsKe
Oral
Pharynx
Larynx
Smoking status
Never smokers
Ever smokers"
Region
Asia
North America
Europe
Year of Publication
1995 - 1999
2000 2002
Number of cases & controls
< 100 cases or < 100 controls
' 100 cases & ^controls
Control Source
Hospital Healthy or Population
Hospital
Matching
Matched / Frequency matched
Not matched
No. of
studies
9
—
3*
—
5*
3«
—
3
4
5
4
—
8
4
5
3
4
OR* for any val(95"*a>
1.10(0 92.1.31)
—
1.52(1.05.2.20)
—
0.94 (0.73. 1.20)
1.15(0.87.1.51)
—
1.11(0.86.1.43)
1.08 (0.85.1.38)
1.15(0.87.1.53)
1.02 (0.82.1.27)
1.06 (0.90.1.24)
0.98 (0.70.1.17)
1.21(1.01,1.45)
1.12(0.89.1.42)
1.18(0.90.1.55)
Test for
Heterogeneity
0.13
—
0.63
—
0.20
0.49
—
0.48
0.14
0.08
0.33
0.24
0.07
0.65
0.47
0.12
Test
No. of
stucfces
11
8*
4*
3*
CYPM1
0R*foranyvali95%CI(
1.50(100.2.26)
1.27 (0 99. 1.63)
1 16 (0.69. 1.94)
1.03 (0.65.1 62)
Test for
Heterogeneity
000
0.19
0 0 9
0.29
Eggers
Test
0.76
093
0.60
0.07
052
0.22
0.42
0.86
0.56
0.94
0.97
0.07
068
0.36
0.56
0.60
0.90
1.29 (0.83. 2.00)
1.05(0.74.1.48)
1.18(0.89.1.57)
1.49 (0.91. 2.43)
1.31 (0.96.1.78)
1.21 (0.89.1.65)
1.44 (0.84. 2.461
1.48(0.72.3.03)
1.21 (0.93.1.57)
0 0 9
0.71
0.23
0.28
0.12
0.19
0.16
0.17
0.24
0.93
0.26
0.01
0.09
0.38
0.50
0 46
0.34
0.98
1. excluded Kao. McWniiams. Sreelekha. 2. included Jourenkova. Katoh. Morita. 3. included Jourenkov^ Matthias. Morita. Oude Ophuis. To-Figueras. 4. included Hahn. Katoh. Morita. Sato. 5.
included Matthias. Morita. Park. 6. included Jourenkova. Katoh. Olshan
a. OR adjusted for study center t>. ever smoking was categorized by different criteria ,n the studies: (30.: 3 ^ 3 ^ ^ „ ^ I O Q cigarettes in a lifetime (41) and not specifically defined (34).
O
Co
Tabto S. Pooled analysis of case-control studies on the GSTM1, 6S771. GSrPl, CVPlAl polymorphisms and head and neck cancer
Site
PI
Benhamou
Bhisey
Cascorbi
Coutelle
Hamel
Katoh
Lazarus
Manni
Romkes
Strange
Strange
Reference
Jourenkova (30-32
Buch(12)
unpublished
Coutelle (25)
Hamel (28)
Katoh (34.35)
Park (43-45)
Country
) France
India
Germany
France
Canada
Japan
USA
Oude Ophuis (21.42) Netherlands
unpublished
Deakin (26)
Matthias (37.38)
USA
USA
Germany
Control Source
Hospital
Hospital. Healthy
Hospital. Healthy
Alcoholic Clinic
Mixed
Healthy
Hospital
Hospital. Healthy
Healthy
Hospital
Hospital
Oral
X
X
X
X
X
X
Pha-
rynx
X
X
X
X
X
La-
rynx
X
X
X
X
X
X
Head & Neck
X
X X X
Cases
250
300*^'
505®
392.3.4
1961®
45
185®
245*®
40®
107®
422®
Controls
172
' 6 7 8 ^ *
223®
7g2.3.4
199®
91
367®
159®
70®
493®
238®
No of studies (cases/controls) in data
Summary OR*
Test for heterogeneity
Publication bias (Eggers testl
1
Oral
Pharynx
Larynx
GS7AM OR (95%CI)
1.09(0.74.1.60)
1.73(1.49. 1.99)*
2.01(1.34.3.01)
2.37(1.05.5.36)
1.09(0.74.1.62)
1.5910.78.3.27)
1.40 (0.96. 2.03)
1.33 (0.77. 2.29)
0.79(0.36.1.73)
0.69 (0.45.1.05)^
1.31 (0.94. 1.83)
9(1.820/1.352)'
1.35(1.13.1.61)
0.27
0.78
1.24(0.97.1.57)
1.25 (0.98.1.61)
1.53(1.17. 2.00)
GSTTl OR (95%O)
1.38 (0.82. 2.30)
1.61(1.11.2.33)
1.26 (0.65. 2.43)
1.15 (0.67.1.98)
0.56 (0.30. 1.05)
0 84 (0.25. 2.84)
1.38(0.84.2.27)
1.54 (0.91. 2.63)
8(1.929/1.830)
1.25(1.00.1.57)
0.22
0.14
1.34 (0.99. 1.82)
1.11 (0.66. L87)
1.10(0.81.1.49)
GS7P1 Any Val
OR (95%CI)
1.23 (0.83. 1.82)
0.87 (0.57, 1.33)
0.77 (0.52.1.14)
1.53 (0.94. 2.48)
1.56(1.11.2.19)
5(1.164/982)
1.15(0.86.1.53)
0.04
0.75
1.37 (0.88.2.14)
1.10(0.58.2.05)
108 (0.81.1.44)
CYPlAlAnyVal
OR (95%CI)
_
1.06(0.76.1.48)
1.02 (0.51. 2.04)
,
0.63(0.33.1.19)
2.11 (0.85, 5.24)
0.87 (0.55.1.38)
5(1.558/1.467)
0.98(0.75.1.29)
0.28
0.79
0.97 (0.56.1.69)
0.77 (0.47. 1.25)
0.9310.64.1.34)
Never smokers
Ever smokers
Caucasians
SCC
1.37 (0.84. 2.23) 1.29 (0.83.1.99) 1.38 (0.46.4.12) 0.95 (0.62.1.45)
1.30 (1.07.1.59) 1.23 (0.77. 1.94) 1.01 (0.76. L33) 0.87 (0.50.1.51)
1.29(1.04.1.59)
1.25(1.05.1.47)
1.17 (0.91. 1.50)
1_17 (0.88. 1.55)
1_ 15 (036. L54) 0.95 (0.64.1.43)
1.13(083.1.54) —
1. prevalent & incident cases, 2. all ever tobacco smokers and/or cnewers. 3. all drinkers. 4. all males. 5. studies excluded from final model. 6. number of cases and controls genotyped
varied for each polymorphism, thus overall numbers are presented. 7 excluded Buch. Deakin
a. OR adjusted for study center
Discussion
The results from the meta-analysis supported the hypothesis that GSI/vfl, GSTT1 and
CVP1/U polymorphisms increase the risk of head and neck cancers. Sources of hete-
rogeneity included sample size among the GS7M1 studies, and geographic region, pe-
riod of publication, and matching among the GS7T1 studies. The pooled analysis
confirmed the association of head and neck cancers with GS7M1 and GS7T1 but the
associations with GSTP1 or CVP1A1 polymorphisms were not clear. The pooled analy-
sis was based on a subset of published studies from the meta-analysis that tended to
report no associations or weak associations. Gene-gene and gene-environment inter-
actions were not identified but a relationship was suggested between an increasing
number of high risk GST genotypes and the risk of head and neck cancer.
Case-control studies with small sample size (less than 100 cases or 100 controls) may
be reporting inflated ORs for the GSr/Wl nu// genotype. These results may suggest cau-
tion in the interpretation of small case-control studies. Our summary estimates on the
effect of the GS7T1 polymorphism may differ for the 3 general regions where the stud-
ies were conducted. A higher summary estimate was seen from studies in Asia for the
GS7T1 genotype. The distribution of GS7T1 nu// in controls was low in the studies from
India (12,22) and when we excluded the 2 Indian studies, the summary estimate for
Asia was no longer elevated (OR-1.34, 95%CI-0.75, 2.39). A detailed assessment of
the role of this polymorphism in India goes beyond the scope of this study.
Studies on GS7T1 and head and neck cancers that were published since the year
2000 report an elevated summary risk, whereas studies published before 2000 did
not. Though publication bias may be suspected for the more recent studies, it was not
suggested by Egger's test (p=0.18). A change in genotyping methods could be a possi-
ble explanation, but all studies had used PCR to amplify the GS7T1 gene and most
studies mentioned using positive controls. Furthermore, since we were unable to con-
trol for matching factors in the meta-analysis, we may have bias in our study-specific
effect estimates. However, matched studies did not seem to have ORs that were
biased toward GS7T1 nu// as might be expected, when compared to unmatched stud-
ies. The heterogeneity observed between studies due to year of publication and
matching status may reflect other study characteristics.
Carcinogen metabolism is complex, involving the interaction of numerous carcinogens
and enzymes. The GSTs have a variety of substrates including environmental carcino-
gens, pesticides, drugs and endogenous molecules of lipid peroxidation as well as in-
ducing agents, some of which double as substrates including polycyclic aromatic
hydrocarbons, phenolic antioxidants, isothiocyanates, and reactive oxygen species
(57). The metabolic action of GST enzymes may differ by tissue type, as the GSTP1 en-
zyme has been observed to be at the highest concentration in oral and pharyngeal tis-
sues and the GSTM1 enzyme at the highest concentration in laryngeal tissue, relative
to the other GSTs (2). GST enzyme expression levels may also differ by general controls
of gene expression, such as the rates of transcription, translation and degradation as
well as possible posttranslational modifications.
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Individually these metabolic polymorphisms may be weak to moderate risk factors, ex-
plaining the inconsistent results seen in epidemiologic studies. The meta-analysis sup-
ported the hypothesis that GSTVfl, GS7T1, and CVPJMl polymorphisms are moderate
risk factors for head and neck cancer. On the other hand, combinations of genotypes
that each confers a small relative risk may sum to a large enough relative risk that can
be observed in epidemiologic studies. Our pooled analysis supported the idea that
multiple GST polymorphisms combined may confer a greater risk of head and neck
cancers. Future epidemiologic studies focusing on combinations of polymorphisms
within the same gene family or other related gene families may be helpful in identifying
individuals at high risk for head and neck cancers and in elucidating gene-gene inter-
actions.
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SUMMARY, CONCLUSIONS. DISCUSSION AND
FUTURE PERSPECTIVES
The incidence of head and neck squamous cell carcinoma (HNSCC) is strongly related
to the consumption of alcohol and tobacco. However, the majority of the individuals
consuming alcohol and tobacco ultimately do not develop HNSCC and therefore seem
to be not susceptible to these hazardous substances. The explanation may be that
considerable inter-individual differences exist in the detoxification capacity for alcohol
and carcinogens of tobacco smoke. Several complex families of phase I and phase II
detoxification enzymes exist, the levels of which may vary from one individual to an-
other, as a result of induction or inhibition by dietary or lifestyle factors. In addition, ge-
netic differences between individuals may also contribute to the actual differences in
detoxification enzyme levels. The latter differences may be largely caused by genetic
polymorphisms in detoxification enzymes, the knowledge on which is rapidly evolving
during the last decade.
The overall aim of this thesis was to provide more information on the occurrence of ge-
netic polymorphisms in cytochrome P4501A1 (CYP1A1) and glutathione S-transferase
(GST) detoxification enzymes in both patients with HNSCC as well as healthy controls,
in order to be able to get insight in the eventual modulating effect of such
polymorphisms on the susceptibility for HNSCC. The summary recapitulates the con-
tents of the individual chapters.
In chapter 1 the mechanism of glutathione conjugation to a potential carcinogen com-
pound is briefly described. Subsequently, an overview is presented on the literature
published to this date concerning the GST polymorphisms in GS7M1, GSTT1 and
GSTP1 and HNSCC susceptibility. The studies so far published have reported contra-
dicting results, and possible explanations for these varying results are given.
In chapter 2 the genetic variability in the corresponding cytochrome P4501A1
(CYP1A1), GSTT1 and GSTM1 isoenzymes. which may contribute to individual diffe-
rences in HNSCC susceptibility, is discussed. By Polymerase Chain Reaction / Re-
stricted Fragment Length Polymorphism (PCR/RFLP) techniques, the different CVP
and GS7" genotypes could be detected in DNA isolated from whole blood, in 185 pa-
tients with HNSCC, 207 healthy blood donors and an additional control group of 78 pa-
tients with benign head and neck lesions (BHNL). The GS7M1 nu// genotype was
demonstrated equally frequent in patients with HNSCC, BHNL and blood donors,
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whereas the GS7T1 nu// genotype occurred significantly more often in patients with
BHNL as compared to blood donors. This could mean that the GS7T1 nu// genotype
may be a risk factor for BHNL.
In chapter 3 we had to revise our findings on the GS7T1 nu// genotype, as published be-
fore in chapter 2, due to demographic variations in the controls. By comparing the GST
M l , Tl and PI genotype frequencies of two healthy blood donor groups from the
Nijmegen and Maastricht regions, we found inter-regional differences. The GSTM1,
GS7T1 and GSTP1 genotype frequencies in two control populations (n=285 and
n-207) from different but neighboring (Maastricht/Nijmegen) geographical regions,
were determined by PCR/RFLP methods. For the GS7T1 nu// polymorphism we found a
significant difference (p-0.003) between the two control groups. When the risk for
HNSCC (all patients are from the Maastricht area) is estimated versus the Maastricht
control group, we now found significantly less HNSCC patients with the GS7T1 nu// ge-
notype as compared to the controls. In contrast to our earlier conclusion, we now have
to conclude that GS7T1 nu// genotype appears to be involved in the modulation of the
risk for HNSCC and not for BHNL.
In chapter 4 we evaluated the role of the GSTP1-1 enzyme plasma levels as a tumor
marker in patients with different sites of HNSCC. GSTP1-1 enzyme levels were mea-
sured in plasma of patients and controls, using a sensitive and specific sandwich En-
zyme Linked Immuno Sorbent Assay (ELISA). Median GSTP1-1 plasma levels of
patients with oral/oropharyngeal, hypopharyngeal and laryngeal sites of HNSCC were
significantly elevated when compared to GSTP1-1 levels from patients with BHNL, who
served as controls. Overall however, only 13 out of 93 patients with HNSCC had ele-
vated plasma GSTP1-1 levels, which makes GSTP1-1 not suitable as plasma tumor
marker for HNSCC.
In chapter 5 we studied the frequencies of polymorphic variants in the GSTP1 gene, in
patients with HNSCC and healthy controls. In patients with HNSCC and controls, the
homozygous GSTP1BB genotype was observed in 12.3% and 13.6% respectively. Also
no statistical differences were found for the distribution of the GSTP1 AA and GSFPl
AB genotypes between patients and controls. This study showed that genetic
polymorphisms in GSfPl are not associated with an altered susceptibility to HNSCC.
Many authors have studied the GSTP1 genotypes in relation to the risk for HNSCC. In
chapter 6, the correlation between GSTP1 genotype and GSTP1-1 enzyme plasma le-
vels was evaluated. GSTP1 genotype and GSTP1-1 plasma levels were measured in
HNSCC patients and patients with BHNL who served as controls. For all GS 7P1 geno-
types (AA. AB and BS) in HNSCC patients, the mean plasma GSTP1-1 values were sig-
nificantly higher compared to the corresponding control groups. However, there was
no significant difference in the plasma GSTP1-1 levels between the different groups of
GSfPl genotypes in HNSCC patients.
Since chemical modification of compounds to be detoxified is very complex and often
requires several subsequent chemical reactions, with corresponding enzymes, we
evaluated in chapter 7. whether the concurrent lack or dysfunction of one or more GST
and Epoxide Hydrolase (EPHX) genes, influences the susceptibility for HNSCC. No sig-
110
nificant difference was found between the group of HNSCC patients and the healthy
controls with respect to the co-occurrence of zero to four (0 - 4) different genetic
polymorphisms. We conclude that multiple polymorphisms in the GST and EPHX genes
are not associated with a higher susceptibility for HNSCC.
In chapter 8 a meta-analysis on the association between HNSCC and genetic
polymorphisms in CYPlvU, GSfMl. GS7T1 and GSIP1 is presented in the form of an
international collaborative study, including the results of 30 published case-control
studies, including 4,286 head and neck cancer cases and 5,440 controls. Subse-
quently, in a pooled analysis of original data from 9 published and 2 unpublished case
control studies (2,324 cases and 2,766 controls), the same associations as well as po-
tential gene-gene and gene-environment interactions were explored. The summary
Odds Ratios (OR) from the meta-analysis and the pooled analysis suggest a weak asso-
ciation for the GSr/vfl, GS7T1 and CVP1A1 genotypes and head and neck cancer risk.
Conclusions
1. Distribution of GS7T1 genotypes in The Netherlands is variable.
2. Research on the associations between genetic polymorphisms and the modula-
tion of risk for HNSCC therefore should be conducted under strict conditions with
respect to including both cases and controls.
3. Plasma GSTP1-1 can not be used as a tumor marker for the detection or follow up
of HNSCC patients.
4. The GSTPl genotypes and the levels of plasma GSTP1-1 enzyme are not associ-
ated in patients with HNSCC.
5. Meta-analysis and pooled analysis in an international collaborative study show a
weak association of GSFM1, GSTT1 and CVP1A1 genotypes and head and neck
cancer, which becomes weaker when adjusted for study center, age, gender and
race. For polymorphisms in GS7P1, when adjusted for study center, age, gender
and race no such correlation is seen.
Discussion
Our hypothesis that polymorphisms in biotransformation enzymes could increase the
risk of HNSCC is not supported by our case-control studies. In one of the first studies
(chapter 2), we found no association between polymorphisms of the GSTMl, GS7T1
and CVP1A1 genes and a higher risk for head and neck cancer. In the same study, con-
tradictory to the hypothesis, we initially found a significantly higher number of GS7T1
nt/// genotypes in patients with BHNL, which suggested that the GS7T1 nu// genotype
may be a risk factor for BHNL. This conclusion, however, was based on a case popula-
tion recruited from a different geographical area (Maastricht) than the control popula-
tion (Nijmegen). The BHNL group, also patients recruited from the Maastricht area,
served as an additional control group. Later on (chapter 3) we recruited a second con-
trol group, this time from the same region (Maastricht) as our HNSCC and BHNL pa-
tients, since we missed data on alcohol consumption and smoking in the Nijmegen
controls, and we did not expect to find significant differences in the GS7T1 genotype
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distribution between controls collected approximately 125 kilometers apart. The fre-
quencies for the GS7T1 nu// genotype in this Maastricht control group, were compara-
ble to the BHNL patient group, but not to the HNSCC patient group which meant that
the BHNL group in fact served as a representative control group. More important how-
ever, was that these data were in contradiction with already published results (chapter
2). The GS7T1 nu// genotype frequencies were now significantly lower in HNSCC pa-
tients as compared to controls, suggesting involvement of GS7T1 nt/// in the
modulation of risk for HNSCC.
Chapter 4 evaluates the use of GSTP1-1 enzyme levels in the diagnostic stage of head
and neck disease. Several studies have shown elevated GSTP1-1 enzyme levels in
plasma of head and neck cancer patients in the first stage of disease, which declined
after surgical resection of the tumor. In our patient-control groups we found no relation
between HNSCC in any stage and GSTP1-1 plasma levels. We however found, that the
methods for treatment of blood and preparing the plasma are very critical, since
GSTP1-1 is present in large amounts in many blood cells, which may be released into
the plasma when not properly processed. Thus, the procedures carried out in this
study are very critical and the question remains, even if there would have been a posi-
tive correlation, whether such a critical procedure would be of clinical value.
Even though we found that measurement of GSTP1-1 enzyme plasma levels has no
value as a tumor marker, there have been several reports on the GSTP1-1 enzyme to
be present in high concentrations in several types of tumor tissue (head and neck tu-
mors included).
We also evaluated whether a polymorphism of the GS7P1 gene may be involved in
head and neck cancer (chapter 5), but found no correlation. The strong associations
between smoking and laryngeal cancer, and between alcohol intake and oral/
oropharyngeal cancer, was expected because of the different ways carcinogen expo-
sure may take place. Tobacco smoke is passing the larynx as most narrow site of the
airway during in- and exhalation, whereas alcohol containing liquids remain tempo-
rarily in the oral cavity even after swallowing.
Having determined plasma GSTP1-1 enzyme levels and GSTP1 genotype in HNSCC pa-
tients and controls, in chapter 6 a combination of the results of the previous two chap-
ters was made. We hypothesized that the elevated GSTP1-1 plasma levels in HNSCC
patients may be caused by one of the GSTP1 genotypes. The fact that no association
between GSTP1 genotype and phenotype was found, supports our view that the
GSfPl polymorphism alone appears to have minimal effect on GSTP1-1 enzyme activ-
ity in head and neck tissues and HNSCC susceptibility.
A study combining several polymorphisms of the GST and EPHX genes, also shows no
evidence for an effect of these polymorphisms on the risk for HNSCC (chapter 7). In this
study, we only studied the number of polymorphisms of any of these genes in patients
and controls, without adjusting for age. gender, smoking or alcohol consumption.
In chapter 8, an international multicenter meta- and pooled analysis was conducted.
Only weak associations with HNSCC and GSTMl. GSTT1 and CYP1A1 genotypes were
found. The conclusions of this meta analysis support the view of this thesis, that ge-
netic polymorphisms in carcinogen metabolizing enzyme systems like glutathione
S-transferases appear to be of minor importance in the development of HNSCC.
Future perspectives
The process of carcinogenesis is very complex. Even when main sources of the carci-
nogens are known, which are alcohol and tobacco smoke in many of the HNSCC cases,
then the exact ways of the "route of carcinogenesis" are difficult to reconstruct. The
metabolism of alcohol is relatively straightforward, but tobacco smoke contains many
toxic and potentially carcinogenic compounds, the metabolism of each of those may
involve many different enzymes, and a lot of research remains to be done before even-
tually important modulating enzymes may be characterized.
Alcohol dehydrogenase, acetaldehyde dehydrogenase, several other members of the
cytochrome P450 and glutathione S-transferase families, UDP-glucuronosyltrans-
ferases which have recently been associated with HNSCC, N-acetyltransferases and
many other enzymes or polymorphisms in the corresponding genes, may be investi-
gated on their involvement in the modulation of the HNSCC risk.
To be able to perform this research properly, it is very important to have a large blood,
tissue and databank from patients with HNSCC and the proper controls, which has al-
ready been set up. Tissue research may also provide valuable information on local en-
zyme activities.
In all our studies the statistical analyses were limited due to the large contrast in smo-
king and alcohol consumption behavior between patient and control groups. The num-
ber of non-smoking HNSCC patients is scarse, whereas in the healthy control groups
there are almost no heavy smokers and/or alcoholics. Especially these extreme
groups (heavy smoking and heavy drinking healthy elderly controls, and nonsmoking,
non-drinking elderly HNSCC patients) may be of particular interest for head and neck
cancer research, since these individuals may have an extreme good, or an extreme
bad functioning detoxification system.
In this thesis we have shown that head and neck cancer, which is strongly related to
high tobacco and alcohol consumption, does not appear to be modulated by
polymorphisms in some enzymes that detoxify tobacco carcinogens or alcohol, but
many enzymes need to be investigated before definitive conclusions can be drawn.
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SAMENVATTING. CONCLUSIE, DISCUSSIE EN TOEKOMSTIGE
MOGELIJKHEDEN
De mate van voorkomen van plaveisel eel carcinoom van het hoofd hals gebied (head
and neck squamous cell carcinoma, HNSCC) is sterk gerelateerd aan de consumptie
van alcohol en tabak. Echter, bij het merendeel van de personen die alcohol gebruiken
of roken ontstaat uiteindelijk geen hoofd hals tumor. Deze personen lijken nlet vatbaar
voor de kwalijke gevolgen van deze Stoffen. Het lijkt erop dat er behoorlijke verschillen
bestaan tussen personen onderling in de ontgiftingscapaciteit van alcohol en de
kankerverwekkende (carcinogene) Stoffen uit tabaksproducten. Er bestaan enkele
complexe families binnen de fase I en fase II detoxificatie enzymen. Bij deze enzymen
kan de funetie tussen personen onderling varieren door verschil in dieet of levens-
gewoonten. Ook genetische verschillen tussen personen kunnen bijdragen aan ver-
schillen in functie van detoxificatie enzymen. Deze laatste verschillen kunnen vooral
worden veroorzaakt door genetische polymorphismen in detoxificatie enzymen. De
afgelopen tien jaar is hier veel over bekend geworden.
Dit proefschrift heeft tot doel meer informatie te verschaffen over de verschillende
genetische polymorphismen van cytochrnom P450 1A1 (CYP1A1) en glutathion
S-transferase (GST) detoxificatie enzymen in relatie tot de vatbaarheid voor HNSCC.
Deze samenvatting beschrijft de inhoud van de individuele hoofdstukken.
In hoofdstuk 1 wordt het mechanisme van koppeling (conjugatie) van glutathion aan
een potentieel kankerverwekkende stof kort beschreven. Tevens wordt een overzicht
gegeven van de literatuur die tot nu toe is gepubliceerd betreffende de GST polymor-
phismen in GS7M1, GS7T1 en GSIP1 en de vatbaarheid voor HNSCC. Tot op dit
moment zijn veel tegenstrijdige resultaten gerapporteerd en hiervoor wordt een aantal
mogelijke verklaringen gegeven.
In hoofdstuk 2 wordt een studie beschreven waarin gekeken is naar de genetische
variatie van de corresponderende cytochroom P450 1A1 (CYP1A1), GSTT1 en GSTM1
isoenzymen die een mogelijke bijdrage leveren aan de individuele verschillen in vat-
baarheid voor HNSCC. Via polymerase ketting reactie methoden (polymerase chain
reaction, PCR) werden de verschillende CYP en GST genotypen aangetoond in DNA,
verkregen uit bloed monsters van 185 patienten met HNSCC, 207 gezonde
bloed-donoren en een extra controlegroep van 78 patienten met goedaardige hoofd
hals aandoeningen (benign head and neck lesions, BHNL). Het GS7M1 nu// genotype
kwam even vaak voor bij patienten met HNSCC, BHNL en de bloed-donoren. Het
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GS7T1 nu// genotype kwam significant vaker voor bij patienten met BHNL dan bij
bloed-donoren. Als gevolg hiervan zou net GS7T1 nu// genotype een risico-factor kun-
nen zijn voor het ontstaan van BHNL.
In hoofdstuk 3 komen wij terug op onze bevindingen ten aanzien van het GS7T1 nu//
genotype, zoals reeds gepubliceerd in hoofdstuk 2, vanwege demografische verschil-
len in controlegroepen. Bij vergelijking van GS7 M l , 71 en P I genotype frequenties
van twee groepen gezonde bloed-donoren uit de regio's Nijmegen en Maastricht,
bestonden aanwijzingen voor mogelijke regionale verschillen. De frequenties van de
GS7M1, GSTT1 en GS7P1 genotypen in twee controle populaties (n=285 en n=207)
uit verschillende, maar aangrenzende geografische regio's (Maastricht/Nijmegen)
werden bepaald door middel van de PCR methode. Bij vergelijking van deze controleg-
roepen werd een significant verschil (p=0,003) gevonden voor het GS7T1 nu// genotype.
Als de groep patienten met HNSCC uit de regio Maastricht wordt vergeleken met de
nleuwe controlegroep, die eveneens uit Maastricht komt, worden nu significant min-
der HNSCC patienten met het GS7T1 nu// genotype gevonden. In tegenstelling tot onze
eerdere opvatting, moeten wij nu concluderen dat het GS7T1 nu// genotype betrokken
lijkt bij de beinvloeding van het risico op HNSCC en niet op BHNL.
In hoofdstuk 4 werd gekeken naar de bruikbaarheid van GSTPl-1 enzym plasma waar-
den als tumor marker in patienten met verschillende typen hoofd hals tumoren.
GSTPl-1 plasma spiegeis werden bepaald in plasma van patienten en een controle-
groep door middel van een gevoelige en specifieke sandwich Enzyme Linked Immuno
Sorbent Assay (ELISA). De mediane GSTPl-1 plasma spiegeis bij patienten met
HNSCC van de mond/mondbodem/oropharynx, hypopharynx en larynx waren signifi-
cant verhoogd ten opzichte van een controlegroep patienten met BHNL. Slechts 13
van 93 patienten met HNSCC had een verhoogde plasma spiegel van GSTPl-1.
GSTPl-1 is derhalve niet geschikt als plasma tumor marker voor hoofd hals tumoren.
In hoofdstuk 5 werden de polymorphismen van het GSTP1 gen bij patienten met
HNSCC vergeleken met een gezonde controlegroep. Het homozygote GS7P1 Sß geno-
type kwam in deze groepen respectievelijk 12,3% en 13,6% voor. Ook voor GSfPl AA
en GSTP1 Aß werden geen significante verschillen gevonden tussen patienten en de
controlegroep. Dit onderzoek heeft aangetoond dat genetische polymorphismen in het
GSTP1 gen niet lijken bij te dragen aan veranderde vatbaarheid voor het ontstaan van
HNSCC.
Er is door veel onderzoeksgroepen onderzoek gedaan naar een relatie tussen het
GSTPl genotype en het risico voor HNSCC. In hoofdstuk 6 is gekeken naar een relatie
tussen het GSfPl genotype en de GSTPl-1 enzym plasma spiegeis bij patienten met
HNSCC en patienten met BHNL. Voor alle GSTP1 genotypen (AA. Aß en ßß) in pati-
enten met HNSCC waren de gemiddelde GSTPl-1 plasma Spiegels significant hoger
ten opzichte van de corresponderende BHNL groepen. Er werd echter geen significant
verschil gezien van de GSTPl-1 plasma spiegeis tussen de verschillende GSIPl geno-
typen in patienten met HNSCC.
Chemische verandering van Stoffen die ontgift moeten worden is erg complex. Het ver-
eist dikwijls een aantal opeenvolgende chemische reacties die vaak onder invloed van
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enzymen plaatsvinden. In hoofdstuk 7 hebben wij gekeken naar de relatie tussen
gelijktijdige afwezigheid danwel functieverlies van een of meer GST en Epoxide Hydro-
lase (EPHX) genen en de vatbaarheid voor HNSCC. Ten aanzien van het voorkomen
van nul tot vier verschillende genetische polymorphismen werd geen significant ver-
schil gevonden tussen de groep patienten met HNSCC en de gezonde controlegroep.
Wij concluderen dat meervoudige polymorphismen van de GST en £PHX genen de vat-
baarheid voor HNSCC niet lijkt te beinvloeden.
In hoofdstuk 8 wordt een meta-analyse gepresenteerd tussen HNSCC en genetische
polymorphismen van CVPJM1, GST/Ml, GS7T1 en GS7P1. Dit is een internationaal
samenwerkingsverband, waarin de resultaten van 30 gepubliceerde studies zijn opge-
nomen (4286 patienten met HNSCC, 5440 controlepersonen). Hierna zijn de resulta-
ten van 9 gepubliceerde en 2 ongepubliceerde studies (2324 HNSCC patiönten. 2766
controles) onderworpen aan een pooled analyse. Hierbij zijn ook mogelijke gen-gen en
gen-omgevings interacties bekeken. De samenvattende Odds Ratios (OR) van
meta-analyse en pooled analyse suggereren een zwakke relatie tussen GSTMl,
GS7T1 en CVP1A1 genotypen en risico voor hoofd hals kanker.
Conclusies
1. De spreiding van GS7T1 genotypen is in Nederland variabel.
2. Onderzoek naar het verband tussen genetisch polymorphismen en het risico voor
HNSCC dient derhalve onder gestandaardiseerde condities plaats te vinden voor
zowel patienten als controlegroepen.
3. Plasma GSTP1-1 kan niet als tumor marker worden gebruikt voor diagnostiek of
follow-up van patienten met HNSCC.
4. De genotypen van GSTP1 en de GSTP1-1 enzym plasma spiegeis staan niet in
relatie tot elkaar bij patienten met HNSCC.
5. Meta-analyse en pooled-analyse in een internationaal samenwerkingsverband
laten een zwakke relatie zien tussen GST/W1, GS7T1 en CVP.L41 genotypen en
hoofd hals kanker. Deze relatie wordt nog zwakker na correctie voor Studie
centrum, leeftijd, geslacht en ras. Voor de polymorphismen van het GS7P1 gen
werd een dergelijke relatie niet gezien.
Discussie
Onze hypothese dat polymorphismen in biotransformatie enzymen het risico van
HNSCC verhogen wordt niet ondersteund door onze patient-controle studies. In 66n
van onze eerste onderzoeken (hoofdstuk 2), kon geen verband worden aangetoond
tussen polymorphismen van de GST/vfl, GS7T1 en CVP1A1 genen en een verhoogd
risico op hoofd hals kanker. In dezelfde Studie werd, in tegenstelling tot onze hypo-
these, aanvankelijk een significant verhoogd GS7T1 nt/// genotype in patienten met
BHNL gevonden, hetgeen suggereerde dat het GS7T1 nu// genotype wellicht een risico
factor kon zijn voor BHNL. Echter, deze bevinding was gebaseerd op een patienten
populatie uit Maastricht en een controle populatie uit Nijmegen. De BHNL groep
bestond eveneens uit Maastrichtse patienten en diende als een extra controle groep.
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Op een later moment (hoofdstuk 3) werd een tweede controle groep uit Maastricht
samengesteld vanwege het feit dat data betreffende alcohol consumptie en rookge-
drag ontbraken bij de Nijmeegse controle groep. Wij verwachtten geen significante
verschillen in GS7T1 genotype aan te treffen tussen twee controle groepen uit regio's
die geografisch circa 125 kilometer van elkaar zijn gescheiden. De frequenties voor
het GS7T1 nu// genotype in de Maastrichtse controle groep waren vergelijkbaar met
die van de BHNL groep, echter niet met die van de HNSCC patienten groep. Dit bete-
kende dat de BHNL groep in feite een representatieve controle groep was. Belangrijker
echter, was dat deze resultaten tegenstrijdig waren met reeds gepubliceerde resulta-
ten (hoofdstuk 2). Nu waren de GS7T1 nu// frequenties significant lager in patienten
met HNSCC ten opzichte van de controle groep, waaruit blijkt dat GS7T1 nu// genotype
wel betrokken zou kunnen zijn bij het risico op HNSCC.
Hoofdstuk 4 beoordeelt de bruikbaarheid van GSTP1-1 enzym plasma spiegeis in de
diagnostische fase van hoofd hals kanker. Enkele onderzoeken hebben aangetoond
dat bij patienten waarbij zojuist HNSCC was aangetoond, een aanvankelijk verhoogde
GSTP1-1 spiegel in het plasma zou dalen na chirurgische verwijdering van de tumor. In
onze patient-controle groepen kon geen verband tussen HNSCC (in welk stadium dan
ook) en GSTP1-1 plasma spiegeis worden aangetoond. Wel vonden wij de methoden
voor de behandeling van het bloed en de bereiding van het plasma kritiek omdat
GSTP1-1 in hoge mate aanwezig is in veel bloedcellen en in het plasma wordt uitge-
scheiden indien de bereiding niet correct plaatsvindt. Deze procedures zijn dus erg
complex waarbij de vraag blijft bestaan of, zelfs bij een duidelijke correlatie, een derge-
lijke procedure van klinische betekenis zou kunnen zijn.
Ook al hebben wij aangetoond dat GSTP1-1 enzym plasma spiegeis geen nut hebben
als tumor marker, zijn er toch studies die hoge concentraties GSTP1-1 enzym beschrij-
ven in verschillende typen tumor weefsel (inclusief hoofd hals tumoren).
Wij hebben geen verband aangetroffen tussen het polymorphisme van het GSTP1 gen
en hoofd hals kanker (hoofdstuk 5). Wel verwachtten wij conform de resultaten een
duidelijke relatie tussen roken en larynx kanker en tussen alcoholgebruik en
mond/mondbodemkanker vanwege de verschillende manier waarop blootstelling van
de schadelijke Stoffen plaatsvindt. Tabaksrook passeert tijdens in- en uitademing de
larynx, zijnde het meest nauwe deel van de bovenste luchtwegen; alcoholhoudende
dranken verblijven tijdelijk in de mondholte, zelfs na het doorslikken hiervan.
Nadat de GSTP1-1 enzym plasma spiegeis en het GSfPl genotype waren bepaald in
dezelfde patient- en controlegroepen, werden de resultaten in hoofdstuk 6 met elkaar
in verband gebracht. De werkhypothese was dat de verhoogde GSTP1-1 plasma spie-
gels bij patienten met HNSCC wellicht werden veroorzaakt door een van de GS7P1
genotypen. Een verband tussen GSTP1 genotype en fenotype kon niet worden
vastgesteld, hetgeen past bij onze visie dat alleen het GSfPl polymorphisme een
slechts minimaal effect lijken te hebben op de GSTP1-1 enzym activiteit in hoofd hals
weefsel en op de vatbaarheid voor HNSCC.
Een onderzoek waarbij verschillende polymorphismen van de GSIen EPHXgenen wor-
den gecombineerd levert ook geen bewijs op dat deze polymorphismen invloed uitoe-
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fenen op het risico op HNSCC (hoofdstuk 7). In dit onderzoek werd het aantal
polymorphismen van elk van deze genen bepaald bij zowel patienten met HNSCC als
in de controle groep. Hierbij werd niet gecorrigeerd voor leeftijd, geslacht, rookgedrag
of alcohol consumptie.
In hoofdstuk 8 werd door middel van een internationaal multicenter meta- en pooled
analyse een zwak verband gevonden tussen HNSCC en GSTM1. GS7T1 en CYPL41. De
bevindingen van deze meta analyse ondersteunen de visie van dit proefschrift; geneti-
sche polymorphismen in carcinogeen metaboliserende enzym Systemen zoals glutat-
hion S-transferasen lijken van ondergeschikt belang in het ontstaan van hoofd hals
kanker.
Toekomstige mogelijkheden
Het proces van carcinogenese is ingewikkeld. Zelfs al zijn de belangrijke bronnen van
carcinogenen bekend, zoals alcohol en tabaksrook in veel gevallen van HNSCC, dan
nog is reconstructie van wat zieh exact afspeelt tijdens carcinogenese moeilijk. De
metabole omzetting van alcohol is relatief eenvoudig, maar tabaksrook bevat veel toxi-
sche en mogelijk carcinogene Stoffen, waarbij het metabolisme van elk van deze Stof-
fen door veel verschillende enzymen beinvloed wordt. Voordat mogelijk belangrijke
enzymen volledig in kaart zijn gebracht is meer onderzoek noodzakelijk.
Alcohol dehydrogenase, acetaldehyde dehydrogenase, enkele anderen van de cyto-
chrome P450 en glutathion S-transferase families, UDP-glucuronosyltransferasen
welke recentelijk in relatie zijn gebracht met HNSCC, N-acetyltransferasen en veel
andere enzymen of polymorphismen in de corresponderende genen, kunnen nog wor-
den onderzocht op hun invloed op het ontstaan van hoofd hals kanker.
Om in Staat te zijn een gedegen onderzoek te verrichten is het heel belangrijk om een
grote bloed-, weefsel- en databank te hebben van patienten met HNSCC en van de
juiste controles. Dit project is reeds gestart. Weefsel onderzoek kan nog belangrijke
informatie verschaffen over lokale enzym activiteiten.
De statistische analyse in alle onderzoeken van dit proefschrift was beperkt vanwege
het grote verschil in rook- en alcoholconsumptie gedrag tussen patient- en controle-
groepen. Het aantal niet-rokende patienten met HNSCC was klein, terwijl in de
gezonde controle groepen vrijwel geen zware rokers en/of drinkers waren. Met name
deze extreme groepen (zwaar rokende en zwaar drinkende gezonde oudere controle
Personen en niet rokende, niet drinkende oudere patienten met HNSCC) zijn van bij-
zonder belang voor hoofd hals kanker onderzoek, omdat deze personen wellicht een
extreem goed of extreem siecht funetionerend detoxificatie systeem hebben.
In dit proefschrift hebben wij laten zien dat hoofd hals kanker, dat duidelijk een relatie
heeft met overmatig roken en alcoholgebruik, niet beinvloed lijkt te worden door poly-
morphismen in een aantal enzymen dietabak en alcohol detoxificeren. Nog veel meer
enzymen zullen moeten worden onderzocht voordat hierovereen definitieve uitspraak
gedaan kan worden.
119
120
DANKWOORD
De laatste loodjes wegen het zwaarst. Dit zullen velen hebben ervaren rondom de af-
ronding van een proefschrift. Dan eindelijk is het moment aangebroken om na te
denken over het dankwoord. Dit blijkt dan ook nog eens een van de drukste momen-
ten te zijn, waarbij het gevaar bestaat dat bepaalde mensen worden vergeten. Daarom
wil ik iedereen bedanken die bij heeft gedragen op welke manier dan ook aan de tot-
standkoming van dit proefschrift. Een aantal mensen wil ik in het bijzonder bedanken
voor hun belangrijke bijdrage.
Prof. dr. J.J. Manni, beste Hans, ik ben je zeer dankbaar dat ik door jou in de gelegen-
heid ben gesteld om niet alleen KNO-arts te mögen zijn, maar daarnaast het vak ook
vanuit de basaal wetenschappelijke kant te mögen ervaren. Als de dag van gisteren
herinner ik me mijn sollicitatiegesprek waarin mijn oncologische interesse ter sprake
kwam; hierin ben je mij volledig tegemoed gekomen. Ik vond het een voorrecht om met
je te mögen samenwerken, waarbij ik vaak het gevoel kreeg met een "Superman" te
maken te hebben.
Dr. W.H.M. Peters, beste Wilbert, zonder jou was ik waarschijnlijk nog steeds met
hoofdstuk 1 bezig. Bijzondere dank voor al je constructieve commentaren en aanvul-
lingen. De overdracht van je encyclopediale kennis op het gebied van ontgiftingsenzy-
men was altijd even verrassend als nuttig. Je stond altijd klaar om in te springen waar
noodzakelijk. Bij afronding van dit project is gelukkig een vervolg in zieht waardoor
onze samenwerking niet zomaar eindigt.
Zonder oncologische patienten was dit onderzoek nooit tot stand gekomen. Dit is gro-
tendeels te danken aan Dr. Johan van de Beek, die in mijn assistententijd "het gezicht"
was van het Hoofd Hals team in Maastricht. Johan, jij bracht mijn database van pati-
enten voor dit onderzoek tot leven, zowel door onze gezamenlijke Hoofd Hals spreek-
uren als de vele chirurgische ingrepen die ik onder jouw toezicht heb mögen doen.
Het lab gastroenterologie van het UMCN en in het bijzonder Hennie Roelofs en Theo
Mulder wil ik bedanken voor hun kundige PCR analyses van het DNA materiaal dat
steeds maar weer vanuit Maastricht overkwam.
121
De analisten van het lab speciele hematologie van net AZM wil ik bedanken voor hun
enorme inspanningen die zij steeds maar weer verrichtten voor de ficol-scheiding van
plasma en later het opslaan van volbloed. De buisjes bleven en blijven maar komen!
Willem Kelders, als co-assistent raakte je meteen enthousiast voor mijn onderzoek,
waarbij je bijdrage ook terecht is bekroond met een publicatie. Onze brainstorming
over enzymen en DNA was altijd plezierig. Je bent ook een goede "back-up" gebleken
toen mijn aktentas met "harde" data uit de auto was ontvreemd. Je zal het nog ver
gaan schoppen.
De leden van de beoordelingscommissie te weten Prof. dr. ir. P.A. van den Brandt
(voorzitter), Dr. B.J.M. Braakhuis, Prof. dr. G.J. Hordijk, Prof. dr. Ph. Lambin, Prof. dr.
F.C.S. Ramaekers wil ik bedanken voor hun tijd en interesse die zij hebben besteed
aan het beoordelen van het manuscript.
Mijn ex-collega assistenten uit Maastricht: Anja, Ingrid, Jaap, Liesbeth, Jan, Lysandra,
Janny, Rico, Harriet, Susan, Martijn. Jullie konden de gebeurtenissen rondom de oplei-
ding en het "GST" onderzoek relativeren naar een "GTST" verhaal (Goede Tijden Siech-
te Tijden). Ook dank voor jullie medewerking aan het verzamelen van patienten. Ik
hoop dat wij nog steeds jaarlijks een en ander kunnen blijven evalueren op het HjO.
Mljn goede vriend en collega Jaap van Twisk, tevens paranimf, brother in arms, vele,
vaak nocturnale, verhelderende sessies aangaande het ST gedeelte van GTST hebben
mij en ook jou op de been gehouden. Met plezier kijk ik hier op terug.
Ook wil ik niet voorbijgaan aan de steun die ik altijd heb gekregen van de verpleegkun-
digen van afdeling A-2, de dames en heer van de polikliniek, alsmede het medisch- en
stafsecretariaat van het AZM.
De maatschap Keel-, Neus- en Oorheelkunde van VieCuri Medisch Centrum voor
Noord Limburg, te weten Patrick Dammeijer, Welty Elprana en Eric Theunissen, heeft
steeds interesse getoond in de voortgang van dit proefschrift, hetgeen ook mede heeft
geleid tot daadwerkelijke afronding ervan.
Mijn broer, collega en paranimf Dr. Ton Oude Ophuis heeft mij voortdurend aange-
spoord tot afronden van mijn onderzoek. Jij hebt mij laten zien bij je eigen promotie
hoe de klus geklaard dient te worden.
Mijn ouders, de Ouwe en de Moe, wil ik bedanken voor de steun die ze mij steeds weer
hebben geboden waar nodig. Voor sommige adviezen kun je alleen maar bij je ouders
terecht. Ook jullie hebben mij altijd tijdens dit onderzoek gestimuleerd.
Last, but surely not least, mijn eigen gezin. Eindelijk komt er nu een tijd waarin ik on-
voorwaardelijk kan genieten van de levens-stappen van mijn oogappeltjes Martijn
(Oekjes) en Janneke (Moekjes). Het lijkt mij heerlijk om jullie nu de volledige aandacht
te geven die jullie verdienen. Papa zal zieh in zijn vrije tijd met jullie zeker niet vervelen.
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Lieve Marianne (Beest), alleen jij weet echt hoeveel tijd dit onderzoek ons heeft ge-
kost. De afgelopen 3 jaar hebben wij in sneltreinvaart een serie "life-events" meege-
maakt, waarbij deze een van de hekkensluiters zal zijn. Behind every ab/e man is an
ab/e woman. Dit adagium is door jou ontstaan! Ik heb veel respect voor de manier
waarop jij de zaken in ons uitbreidende gezin steeds weet te regelen, temeer daar ik
nogal eens "bezig was" voor net onderzoek. Jouw trouwe steun, geduld en liefde zullen
nu ook eindelijk worden beloond. Beest bedankt!
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CURRICULUM VITAE
Michel Oude Ophuis werd op 4 mei 1967 geboren te Hillegersberg in Rotterdam. Van
1979 tot 1985 was hij woonachtig in McLean, Virginia, USA. Aldaar heeft hij op Langley
High School gezeten tot 1983. Met het oog op een studie in Nederland werd vanaf
1983 de opleiding voortgezet aan de Washington International School te Washington
DC, waar hij met succes het International Baccalaureate Diploma heeft behaald In
1985. Vervolgens werd gestart met de studie Geneeskunde aan de Katholieke
Universiteit Nijmegen. Het propaedeutisch examen werd in 1986 en het doctoraal
examen in 1989 behaald. Tot aan zijn co-assistentschappen in 1990 werden ex-
tra-curriculaire stages Heelkunde / Plastische Chirurgie gevolgd aan het Mubarak al
Kabeer Hospital in Kuwait, alsmede een onderzoekstage binnen de afdeling Plastic
and Reconstructive Surgery (Prof. dr. D.A. McGrouther) van University College London.
In 1993 werd het artsexamen behaald. Na werkzaam te zijn geweest als arts-assistent
cardiochirurgie niet in opleiding in het Universitair Medisch Centrum Nijmegen (Prof,
dr. L.K. Lacquet), startte hij op 1 januari 1995 met de opleiding tot Keel, Neus- en
Oorarts in het Academisch Ziekenhuis Maastricht onder leiding van Prof. dr. J.J. Manni.
De B-opleiding vond plaats in het Atrium Medisch Centrum te Heerlen bij Dr. T.D.
Zijlker. Tijdens zijn opleiding werd onder leiding van Prof. dr. J.J. Manni en Dr. W.H.M.
Peters gestart met het wetenschappelijk onderzoek dat uiteindelijk heeft geleid tot dit
proefschrift. Sinds 1 januari 2000 is hij werkzaam als Keel-, Neus- en Oorarts in
VieCuri Medisch Centrum voor Noord-Limburg. Hij is getrouwd met Marianne
Steenmetz. Zij hebben twee kinderen, Martijn en Janneke.
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